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Abstract 
BACKGROUND: Vitamin B12 status is a relevant topic to older adults and deficiency has avoidable 
clinical ramifications.  While classical symptoms of B12 deficiency are either hematologic or 
neurologic, presentation of these symptoms are not reliable as diagnostic tools as they are not present 
in all cases. Furthermore, symptoms of subclinical deficiency are nonspecific; a blood test is required 
for B12 status determination and as a first step towards treatment. B12 screening and treatment 
protocols in LTC have not been documented and no studies have been designed to establish vitamin 
B12 deficiency prevalence at admission or to describe incidence within this population. Furthermore, 
studies on prevalence using a cross-section of the LTC population lack representativeness.  
PURPOSE: The purpose of this thesis was to investigate vitamin B12 status in Ontario LTC homes. 
In particular, this thesis aimed to establish: what protocols and procedures are used in LTC for testing 
and treatment for B12 deficiency; the prevalence and what resident characteristics are associated with 
B12 deficiency at admission; and the incidence of B12 deficiency one-year post-admission. 
METHODS & FINDINGS: Two studies were conducted as part of this thesis work.  
Study 1: Forty five Ontario LTC homes were recruited using stratified random sampling 
from two sample frames, representing 5243 residents in this cross-sectional study. Phone interviews 
were conducted with directors of care using a standardized interview schedule for data collection. 
Interviewees were asked about policies and procedures for B12 testing, proportion of residents 
receiving B12 treatment and modality (oral, intramuscular, subcutaneous) used for B12 
supplementation in their LTC home. Two-thirds (30/45) of participating sites routinely tested for B12 
at admission, and 88% (34/40) of reporting homes conducted follow-up B12 testing. Furthermore, 
cut-off levels to define B12 deficiency varied between homes, presenting a challenge to determine 
prevalence. On average, 25% of current residents were receiving B12 supplements; the most common 
treatment modality was intramuscular injections (53%) followed by oral supplements (44%). Due to 
variability in practices relating to detection and treatment of B12 deficiency, LTC residents are 
potentially at risk for undetected deficiency.  
Study 2: A retrospective prevalence study was conducted across eight sites in Southwestern 
Ontario within one LTC organization. Random proportionate sampling was used to identify resident 
charts for inclusion, with replacement as necessary. Eligibility criteria were: residents being 65 years 
or older at admission and presence of admission bloodwork, including serum B12 levels. Resident 
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characteristics considered for this study included: basic demographics, B12 supplementation prior to 
admission, medications, diagnoses, functional independence, cognitive performance, and nutritional 
status. 1005 charts were screened to obtain 412 total eligible residents. Average B12 deficiency 
prevalence at admission was 14% but only 48% of residents had normal B12 status at admission. 
Admission B12 status was significantly and positively associated with supplementation prior to 
admission (χ2=60.8, p<0.001). There was a significantly (p<0.01) higher proportion of B12 
supplementation in those with dementia than those without. Prevalence and incidence of B12 
deficiency one year post-admission was 7% and 4% respectively. With numerous sites and large 
sample size, the present study provides better insight into B12 status than previous work, and is the 
first to report both admission prevalence as well as one-year incidence. In general, B12 status in this 
LTC sample was poor, yet supplementation was a protective factor.  
OVERALL CONCLUSIONS: A relatively large proportion of LTC residents are impacted by B12 
deficiency. While some protocols are in place for testing and treatment, some LTC residents are 
potentially at risk for undetected B12 deficiency. Treatment methods are generally effective, and 
should be used to deter progression to a deficient state. Prevalence was consistent with previous 
findings, including a high degree of variability depending on the cut-point used to define deficiency. 
This will remain a challenge, however screening, treating, and monitoring is important to prevent 
clinical manifestations, and deter symptoms associated with subclinical deficiency from presenting. 
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Chapter 1 
Introduction 
This thesis has been a very personal journey for me. All of this work stemmed from my own B12 
deficiency experience, rooted itself in my exposure to Professor Keller’s work with micronutrients 
which then flourished into a quest to seek answers and advance our understanding of B12 deficiency 
in long-term care, with an underlying aim to enhance quality of life and care with these learnings.  
Vitamin B12 deficiency has tangible endpoints with known consequences such as anemia and 
neurological damage. When I was diagnosed with B12 deficiency, I had neither of those classic 
endpoints despite my deficient status by any of the prevailing cut-points. I went to the doctor with 
complaints of tiredness, inability to concentrate and, quite frankly, grumpiness. My experience and 
amelioration of symptoms with proper treatment opened my eyes to the magic of adequate B12 status 
and provided me with a healthy respect for how my nonspecific symptoms were related to a nutrient, 
which when deficient could impact my ability to live life to its fullest.  
Working at the RIA opened my eyes further, this time, to the world of long-term care, a population 
where every ounce of independence counts. At one of Professor Keller’s presentations at operational 
planning, she mentioned how older adults are more likely to be B12 deficient. With that, my interest 
was piqued.  How big of a problem was this? What proportion of residents like me, are impacted by 
B12 deficiency and how could this impact their quality of life? How is B12 deficiency identified and 
treated in long-term care?  These questions, based in personal experience, are the basis for this thesis.  
This thesis consists of several chapters that summarize my learnings and answers many of the 
questions outlined above. Chapter 2 provides background on vitamin B12 including: what is B12; its 
biological roles; how it is metabolised and measured; how vitamin B12 status is defined; why vitamin 
B12 is important to residents in LTC and factors that can influence B12 status in this population and 
beyond. Chapter 3 provides rationale and poses research questions for the subsequent two research 
chapters. Two studies were conducted as part of this thesis work, each of which are outlined in an 
individual chapter in manuscript form (Chapters 4 and 5), followed by Chapter 6, the overarching 
discussion linking the manuscripts back to the research questions and providing main conclusions.  
I hope you enjoy this journey through my curiosity and learnings. 
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Chapter 2 
Background: The what, how, and why for studying B12 deficiency 
in LTC 
2.1 What is vitamin B12? 
Vitamin B12 is a water-soluble essential micronutrient required for: the production of blood cells, 
maintaining nerves, regulating B12-dependent processes (see What are the biological roles of vitamin 
B12? on page 3), and maintaining intact gastrointestinal mucosa [1]. Vitamin B12 is the only water 
soluble vitamin stored by the human body for any sufficient time; the liver is the primary storage site 
containing more than 1.5 mg of the vitamin [2]. Since turnover of vitamin B12 is approximately 0.1% 
per day, it would take between 2-10 years for B12 deficiency to develop even when a diet is 
completely lacking in the vitamin [2, 3].  
Vitamin B12 refers to a family of complex molecules with a central cobalt atom surrounded by 
four reduced pyrrole rings, which is referred to as cobalamin. The form of cobalamin or B12 depends 
on the upper axial ligand bond linked to the cobalt atom [1, 4]. While there are five forms of B12 
(methylcobalamin, cyanocobalamin, hydroxycobalamin, aquocobalamin, and adenosylcobalamin [1, 
4]) methylcobalamin and adenosylcobalamin are the only forms of B12 used for metabolic processes 
in the human body.  
2.1.1 Vitamin B12 transport proteins  
There are four known proteins involved in the absorption and transport of vitamin B12: intrinsic 
factor, R-protein (transcobalamin I), transcobalamin II, and transcobalamin III. Intrinsic factor is 
made by parietal cells, which line the stomach. It plays a pivotal role in absorption of B12 from the 
small intestine into blood [4]. R-protein which is also known as haptocorrin or transcobalamin I is 
found in most body fluids [4]. While it has no known function, B12 bound to R-protein accounts for 
80% of total plasma B12 [5, 6] and may contribute to falsely high B12 measurements [7]. 
Transcobalamin II, also known as holotranscobalamin (holoTC) when bound to B12, is found in 
blood plasma [4]. HoloTC is the only biologically active form of B12 and is responsible for the 
transport of B12 to cell membrane receptors (part of receptor mediated endocytosis) [4]. HoloTC 
accounts for 6-25% of total plasma B12 [1, 8, 9] and is believed to be the most sensitive marker to 
depletion or repletion of B12 [5, 9, 10]. Lastly, transcobalamin III is made by granulocytes [4, 11] 
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and has an unknown function [5]. However, it has clinical significance as elevated levels of 
transcobalamin III, as seen in chronic myelogenous leukemia, may cause falsely high measures of 
B12 [4]. 
2.2 What are the biological roles of vitamin B12? 
 
Figure 1: A simplified model of vitamin B12-dependent processes. Adapted from Andrès et al., 2004 
[12]. 
 
While oversimplified, the following section provides an overview of the biological processes in 
which B12 is involved including its relationship to energy metabolism, folate and vitamin B6 and is 
summarized in Figure 1. Two forms of vitamin B12 are essential cofactors for biological processes: 
1) adenosyl-B12 in the mitochondria for proper energy metabolism, and 2) methyl-B12 in the cytosol 
of cells for methylation reactions including nucleic acid synthesis.  
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In the mitochondria, vitamin B12 is involved in oxidation reactions of branch chain and odd-chain 
fatty acids (e.g., threonine, valine, methionine) [13-15]. Vitamin B12 (adenosylcobalamin) is required 
as a cofactor by the enzyme methylmalonyl-CoA mutase for the conversion of methylmalonyl-CoA to 
succinyl-CoA which feeds into the citric acid cycle for energy metabolism [13-15]. In vitamin B12 
deficiency, methylmalonyl-CoA builds up and gets converted to methylmalonic acid (MMA) [14-16] 
which is a myelin destabiliser [17]. It also leads to less succinyl-CoA to feed into the citric acid cycle 
yielding less efficient energy metabolism [14-16]. 
In the cytosol, vitamin B12 is involved in the conversion of the amino acid, homocysteine into the 
amino acid methionine. Vitamin B12 (cobalamin) is required as a cofactor by the enzyme methionine 
synthase for the transfer of a methyl group from 5-methyltetrahydrofolate (derived from folic acid) 
onto B12 (methylcobalamin) to form tetrahydrofolate. The methylcobalamin is then used as a methyl 
donor in the conversion of homocysteine to methionine, through methyl group addition[18]. 
Generated methionine is required for the formation of s-adenosyl-methionine (SAM) which is a 
universal methyl donor for methylation reactions [18]. Vitamin B12 deficiency decreases the amount 
of methionine generated and downstream impacts every cell in the body from the formation of myelin 
[1, 18], neurotransmitters [1, 15], phospholipids [1, 15], to nucleic acid synthesis [18] and RNA and 
DNA methylation [10, 18].  
Due to this metabolism, a by-product of vitamin B12 deficiency is elevated levels of homocysteine 
(Hcy), since it cannot be converted to methionine [17]. Elevated levels of Hcy have been shown to be 
associated with dementia [19, 20], Alzheimer’s [20-22], carotid-artery stenosis [4, 23], stroke [4, 24], 
a three-fold increased risk for myocardial infarction [4, 23], and a four-fold increased odds ratio for 
venous thrombosis [4, 25, 26]. While association does not infer causation, a recent meta-analysis 
provides supporting evidence for an association between low vitamin B12 and folic acid with high 
homocysteine levels [27]. As such, elevated homocysteine levels may be a modifiable risk factor 
amenable to B12 and or folate therapy.  
While vitamin B12 maintains homocysteine levels, so too does vitamin B6 and another compound, 
betaine. Vitamin B6 is responsible for transamination of homocysteine to cysteine, thus improved B6 
status may also reduce elevated Hcy levels or may elevate Hcy levels in the case of B6 deficiency. In 
the cytosol of most cells of the body, betaine is present and is responsible for the conversion of 
homocysteine to methionine through an alternative pathway other than via vitamin B12. While 
betaine can help rescue the effect of B12 deficiency by preventing elevations of homocysteine [21, 
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22, 28, 29], it is not present in the brain, which may increase the importance for adequate B12 status 
with respect to healthy brain function.  
2.3 What are food sources and how is vitamin B12 metabolised? 
Meat and dairy products are the only naturally occurring sources of vitamin B12 as it is created by 
microorganisms. The amount of B12 per serving varies widely depending on the source. For example 
one 250 mL serving of skim milk contains 1.3 mcg; beef liver, tuna, ground beef and chicken contain 
between 52.9-64.4 mcg, 8.2-9.3 mcg, 2.4-2.7 mcg, 0.2-0.3 mcg of B12 per 2.5 oz (75 g) serving, 
respectively; two large eggs contain 1.5-1.6 mcg, and 175 g of fruit-bottom yogurt contains 0.8 mcg 
of B12 [30]. Plant-based foods require fortification [18]. Some examples of foods fortified with B12 
are soy milk (1 mcg per 250 mL serving) [31], and dry cereals, such as All Bran (5.2 mcg per 31 g 
serving) and Multigrain Cheerios (6.2 mcg per 30 g serving) [32]. For foods naturally containing B12, 
vitamin B12 is bound to proteins or polypeptides. However, foods in which B12 has been added 
contain crystalline B12, [33] typically in the form of cyanocobalamin [34]. In the stomach, pepsin and 
hydrochloric acid are responsible for liberating the protein-bound B12 to its free form. The parietal 
cells which line the stomach are also responsible for producing the transport protein, intrinsic factor 
(IF) which plays a later role in absorption [18]. As naturally occurring B12 or non-physiologic doses 
of crystalline B12 empty from the stomach into the upper portion of the small intestine (duodenum), 
the transport protein, R-protein (transcobalamin I), binds to the B12 to form a complex. Once inside 
the duodenum, pancreatic proteases hydrolyze the R-protein to liberate free B12, which then binds to 
IF. The IF-B12 complex is carried from the duodenum through the middle portion of the small 
intestine (jejunum) and to the lower portion of the small intestine (ileum), which contains surface 
receptors for the IF-B12 complex. These surface receptors are called cubam and are comprised of a 
complex of two proteins, cubulin and amnionless. Cubam is responsible for the absorption of the IF-
B12 complex into the intestinal absorptive cells (enterocytes) through receptor-mediated endocytosis 
and the B12 dissociated from IF [11, 13, 18, 35]. 
From here, vitamin B12 is absorbed into portal blood in one of two ways; through the major 
absorptive pathway or the minor absorptive pathway. In the major absorptive pathway, 
transcobalamin II (TCII) binds to the B12. This process accounts for at least 60% of oral B12 
absorption [2]. However, the rate-limiting factor for absorption through this pathway is the capacity 
for the ileum mucosa to endocytose the IF-B12 complex; the maximum capacity is 1.5 µg [1]. The 
minor absorptive pathway is via passive diffusion, which, accounts for approximately 1-5% of 
 6 
absorption [2, 11, 18]. However, physiologic doses of crystalline B12 primarily rely on this minor 
absorptive pathway [11]. Once in the portal blood, B12 is found bound to either TCI (R-protein) 
(~80%), TCII (~20%) or TCIII. Tissues have receptors for TCII and take up the TCII-B12 complex 
via endocytosis. Lysosomes then engulf the TCII-B12 complex and lyse it into free B12 for release 
into the cytosol of the cell [11, 13, 18, 35]. 
While malabsorption affects 10-30% (through atrophic gastritis) of older adults and impacts the 
ability to absorb B12 due to the major absorptive pathway, there is evidence to suggest that the minor 
absorptive pathway (i.e., through passive diffusion) remains intact with age [11, 36]. Thus food 
fortified with B12 is more bioavailable than food-bound B12 and older adults are advised to get B12 
from B12 plant-based fortified foods instead of food-bound B12 [11].  
2.4 How is vitamin B12 status measured? 
Vitamin B12 status can be measured in one of two ways, either through blood (directly or indirectly 
measuring B12) or through urine biomarkers. The most commonly used method is through 
biomarkers directly measuring B12 in serum or by measuring holoTC. Indirect methods use serum 
metabolites of B12-dependent reactions such as methylmalonic acid (MMA) or homocysteine. 
Common methods for testing, a description of the method, reference ranges, sensitivity, specificity, 
and pros and cons are mentioned below; each measurement has its strengths and weaknesses. 
Today, serum vitamin B12 is most commonly measured through a competitive binding 
luminescence assay (CBLA). First, vitamin B12 is liberated to the free form (i.e., not food-bound) of 
a patient’s blood serum which competes with added labelled-B12 (LB12) for binding to a known 
quantity of purified intrinsic factor forming, either IF-B12 or IF-LB12. The IF bound to either B12 or 
LB12 is isolated by binding to paramagnetic beads. Then, a conjugate that specifically binds to the 
IF-LB12 is added followed by a substrate in which to bind the IF-LB12-conjugate. The result is 
chemiluminescence proportional to the amount of IF-LB12 with an inverse relationship of 
luminescence to the amount of B12 added from the patient [3]. The reference range for serum B12 
varies but typically ranges between 78 pmol/L (105 pg/mL) to 258 pmol/L (350 pg/mL) [1, 37-41]. 
The sensitivity of serum B12 is high (between 90-95%) with clinical manifestations (i.e., hematologic 
or neurologic etiologies) [3]. While specificity has not been formally determined, it has been 
estimated to be between 40 and 80% but is worse in the absence of clinical symptoms [3]. One 
primary advantage of this method is that serum B12 tests are relatively inexpensive (i.e., €17 [5], $10-
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15 CAD [42] per test) and is readily available. However, there is a risk of false-negative results from 
confounding factors due to the nature of CBLA. Anything that may interfere and cause decreased 
luminescence will yield an overestimation of B12 levels. In cases of pernicious anemia, there are IF 
antibodies naturally present in the blood sample which interact with the labelled IF [3]. This results in 
less luminescence falsely indicating higher levels of B12 and thus provides a false-negative for B12 
deficiency [3]. Similarly, if luminescence is increased, indicating lower B12, as seen in haptocorrin 
deficiency, folate deficiency, multiple myeloma, HIV, pregnancy and oral contraceptive use, there is 
a risk of false-positive for B12 deficiency results [3]. These false positive and false negatives make it 
more difficult for prevalence estimates to be accurate. Especially in the case of pernicious anemia 
where 2-5% of older adults are affected [43], this may in part account for the wide margin of 
prevalence estimates. 
Holotranscobalamin II (holoTC) is another way to directly measure B12 in serum; blood samples 
are analysed using a holoTC-specific monoclonal antibody assay [9]. Essentially there are two forms 
of antibodies, one to capture the holoTC as it passes by, which is mounted to a sensor chip, and 
another form of free-floating antibodies to detect the holoTC; the holoTC is captured on the chip 
followed by detection that the holoTC is present on the chip [44]. The reference range for the 
holoTC-specific monoclonal antibody assay is said to be between 32-35 pmol/L yielding a sensitivity 
of 75-80% and a specificity of 55-60% [1, 5]. However, poor renal function results in elevated 
holoTC levels [45]. This measurement is still undergoing testing and is not commonly used. 
Specifically, its diagnostic power may not be sufficient to distinguish between deficient and 
nondeficient status and there is evidence to suggest that while holoTC may have low measurement 
variability at levels of B12 ingested from food, it has a high degree of diurnal variation with 
physiologic doses of B12 [9]. The relative cost of holoTC may also be a barrier for its use at €50 per 
test and no readily available cost estimate for Canada [42]. Additionally, holoTC is prone to a higher 
rate of false positives, especially in impaired renal function and liver disease [45]. 
Homocysteine (Hcy) is a surrogate biomarker for B12 that can be measured using high-
performance liquid chromatography (HPLC) with fluorometric detection [19]. HPLC consists of a 
column with specific beads with characteristics complementary to the substance of interest for 
measurement. Once a sample is run through the column, molecules are separated based on their 
affinity for the column, other liquids are passed through the column that interact with molecules 
bound to the column in different ways, eluting them off at different times; this is referred to as 
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retention time [46]. If different molecules have the same binding affinity for the column, they will 
elute off the column at the same time which is problematic; thus, the substance of interest is 
contaminated with another. One way around this is the additional use of fluorometric detection where 
a known wavelength of light interacts with a compound of interest (in this case it is homocysteine) in 
a specific way to produce fluorescence. The degree of fluorescence is proportional to the 
concentration of the compound of interest thus the relative “glow” of the sample indicates how much 
homocysteine is present. Homocysteine is considered to be elevated at concentrations above 10 
µmol/L [1]. The sensitivity of Hcy for vitamin B12 deficiency is very high at over 95%, yet it has an 
unknown specificity [3]. Positives of this test are that it improves diagnostic sensitivity [3] when used 
in tandem with serum B12 and it more accurately portrays the metabolic function at the tissue level 
than does B12 [4]. However, homocysteine is not a specific biomarker for B12 [4]; Hcy is elevated in 
folate deficiency and with certain genetic variants, which decreases the diagnostic utility of Hcy when 
used alone. It is also relatively expensive ($65 CAD per test [42]) compared to serum B12. 
Methylmalonic acid is a surrogate biomarker of B12 since it is a metabolite of a vitamin B12-
dependent reaction [4]. As such, MMA is a measure of functional B12 deficiency and is an unofficial 
gold-standard [3]. MMA can be measured using gas chromatography-mass spectrometry [5]. 
Molecules are separated based on their affinity for a stationary phase of a capillary column within the 
gas chromatograph and the retention time to elution of the molecule followed by a pass through a 
mass spectrometer further separating molecules based on their charge and mass [47]. The reference 
range of MMA is 50-300 nmol/L with a high sensitivity (95%), but undetermined [1] or low 
specificity [3]. Several advantages exist for this method of measurement: it can be assessed in urine 
[4] (using an adjusted reference range) which is less invasive than a blood draw; it can improve 
diagnostic sensitivity [3] when used in tandem with another measurement; it accurately portrays 
metabolic function at the tissue level [4]; and there is some evidence to suggest that it may be a more 
sensitive biomarker for cognitive function [5]. While MMA testing has considerable benefits, it is 
also an imperfect test; its relative cost compared to serum B12 at $105 CAD [42] per test (or €60 [5]) 
is a barrier for systemic use, and false positives are common in those with decreased renal function 
[4]. Since impaired renal function is more common in older adults, the diagnostic utility of this test 
decreases in this population.  
One additional measure is the Schilling test which is used to determine if an individual can absorb 
B12. This test is not used as frequently as it once was because it relies on radio-labelled B12. In phase 
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one of this test, radioactive B12 is given orally, followed by a dose of nonradioactive B12. Phase two 
occurs 24 hours later where radioactive B12 plus intrinsic factor is given followed by a dose of 
nonradioactive B12. Interpretation of the results are as follows: if the results from phase one are 
abnormal and phase two are normal, this implies the individual has absorption problems consistent 
with pernicious anemia (i.e., they do not make sufficient IF for absorption). If both phase one and two 
are abnormal, this implies an alternative cause for B12 deficiency [4].  
2.4.1 Dietary reference intakes (DRIs) for B12 
The dietary reference intakes are a group of reference values (i.e., recommended dietary allowance 
(RDA), adequate intake (AI), tolerable upper intake level (UL), and estimated average requirement 
(EAR)) that provide quantitative estimates of nutrient requirements used in a healthy population for 
planning and assessing dietary intakes [36]. While the RDA is most relevant to this work, it is worth 
noting that no tolerable upper limit has been set [36], despite the relatively long-term storage of this 
vitamin. The RDA represents the intake level that meets the estimated nutrient requirement for 98% 
of a gender and age group within a healthy population. For vitamin B12, in those 70 years or older, 
the RDA has been defined by countries as follows: 2.4 mcg/day in the US, Canada, Australia and 
New Zealand [36, 48, 49], and 3 mcg/day in Germany, Austria and Switzerland [1].  
It is unclear as to whether these recommendations for B12 are appropriate for older adults. There 
is evidence to suggest that mild B12 deficiency needs a daily oral dose of more than 200 times the 
RDA to normalize B12 levels and reverse hematological and neurological symptoms [1]. Yet, the 
average daily intake in the US for community dwelling adults aged 60 years or older, was estimated 
in males and females, respectively, to be 5.4 mcg and 3.7 mcg from dietary intake alone and 17.4 mcg 
and 31.0 mcg from supplemental intake [36]. This implies that, in individuals with mild deficiency, 
even in those taking supplements, older adults are not consuming more than 200 times the RDA and 
therefore cannot normalize their B12 levels without pharmacologic doses of supplements. This may 
be especially problematic for older adults living in long-term care where poor food intake is common 
[50]. 
2.4.2 Common Reasons for Deficiency 
While vitamin B12 deficiency can arise for many reasons, generally, all factors fit into one of the 
following categories: inadequate intake; dysfunction of food-cobalamin absorption; or dysfunction of 
transport.  
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Inadequate intake of B12 may be of concern in a strict vegan diet where normal sources of food-
B12 are avoided. While generally adequate intake is not a concern in older adults, those living in LTC 
may additionally be at increased risk of inadequate intake of B12 due to the high prevalence of 
malnutrition ranging between 30-70% [2, 51, 52]. Despite one study investigating the cause of B12 
deficiency in older adults, reporting only 2% of cases due to insufficient B12 intake [12], others 
report B12 intake to be one third [53] and two thirds [51] below recommendations. It could be 
hypothesized that since older adults living in LTC are more likely to have low B12 intake and that it 
is impossible for this population to normalize their B12 levels through food alone, they are at an 
increased risk for reduced B12 levels, especially if they do not take supplements.  
A fairly recent review identified the leading cause of B12 deficiency in older adults to be food-
cobalamin malabsorption, accounting for 60-70% of cases [2]. Food-cobalamin malabsorption refers 
to the inability to adequately break B12 apart from food or from transport proteins [2, 54] and can be 
caused by a number of factors such as: gastric atrophy either related or unrelated to H. pylori 
infections [8]; bacterial overgrowth [8, 35]; alcoholism [8]; or use of certain medications (H2 
blockers [8], PPIs [8, 55]) or metformin [2, 56-58]. Pernicious anemia occurs in those who lack 
intrinsic factor; older adults with pernicious anemia accounted for 15-33% of B12 deficiency cases [2, 
8, 12, 35]. Diseases that impact absorption more broadly such as lymphoma, Crohn’s disease, celiac 
disease, may also cause B12 deficiency [2]. 
Heredity of rare disease and genetic factors also play a role in B12 deficiency albeit to a much 
lesser extent in older adults since most appear to be autosomal recessive [2]. Imerslund-Grasbeck 
syndrome, a rare disease often diagnosed in the first few years of life, impacts intestinal transport of 
B12 in which cell surface receptors responsible for receptor-mediated endocytosis fail to function 
properly [59]. Additionally numerous other genetic mutations may impact B12 status through 
ineffective transport proteins or the ability to create intrinsic factor [13, 59]. 
2.4.3 Symptoms of B12 deficiency: 
If left untreated, vitamin B12 deficiency will likely result in the classical endpoints of hematologic or 
neurologic complications. Seventy-five to 90% of those with B12 deficiency have neurologic 
symptoms and approximately 25% of patients with neurologic symptoms do not present with any 
hematologic abnormalities [1, 2, 4, 11]. Neurologic symptoms may result in paralysis from either 
subacute combined degeneration of the spine or funicular spinal cord disease, unsteady gait or skin 
numbness [1]. Hematologic abnormalities include pernicious anemia [8] and macrocytic anemia [8]. 
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If left untreated, damage becomes irreversible. However there is evidence to suggest there is a 
window of opportunity in which to reverse these symptoms [60] highlighting the importance of 
diligent testing (in the absence of symptoms) and treatment of deficient cases [11, 61]. 
Additionally, symptoms relating to subclinical B12 deficiency are diverse making it difficult to 
pinpoint B12 status as the potential cause. These symptoms include: lethargy [22, 62] or fatigue [2], 
depression [22, 62, 63], cognitive decline or dementia [22, 62, 63], increased confusion [62], 
forgetfulness [22, 62], peripheral neuropathy [2, 14, 63], osteoporosis [14]. With such diverse 
symptoms, many of which affecting the ability to live life normally, regular testing and treatment 
when appropriate is important. 
2.5 Defining vitamin B12 deficiency 
Part of the challenge in establishing prevalence is inconsistency in defining vitamin B12 deficiency. 
Several cut-points have been suggested: 125 pmol/L [64], 148 pmol/L [38, 65], 150 pmol/L [39], 184 
pmol/L [66] and 258 pmol/L[40]. Traditionally, a cut-point of 148 pmol/L has been used [59]. Cut-
points are also lab dependent and drives the diagnosis dependent on the value used [67]. Several other 
definitions have also been introduced using a combination of cut-points for B12 and either other 
biomarkers (e.g., MMA, Hcy, holoTC) or other blood related symptoms [2, 40]. While surrogate 
biomarkers for vitamin B12 status (e.g., methylmalonic acid) may presently be regarded as the gold 
standard and improve diagnostic sensitivity [3], practicality of determining vitamin B12 deficiency is 
dependent on the measures that are covered by medicare and/or those available at a given commercial 
lab.  
2.5.1 Defining a serum B12 level for “normal” and “subclinical deficiency” 
For this thesis, a distinction was made between deficient, subclinical and normal B12 status as 
deficiency exists on a continuum [10, 68]. Some literature provides evidence to support that “normal” 
serum B12 should be a minimum value of approximately 300 pmol/L [1, 14, 69-71]. Eussen and 
colleagues used a range of 100-300 pmol/L to define mild deficiency in a dose-finding trial for 
vitamin B12 intake that resulted in optimal reduction in plasma methylmalonic acid [69]. Elevated 
methylmalonic acid is a sensitive biomarker for vitamin B12 deficiency. Additionally, Clarke and 
colleagues reported that the range of serum vitamin B12 that corresponded with a low risk for 
elevated homocysteine was 350-400 pmol/L [70]; homocysteine is a known cardiovascular risk factor 
[10, 59, 72], potentially a neurotoxin [1, 10] and vasculotoxin [10], and elevated levels 
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(hyperhomocysteinemia) are an independent risk factor for dementia and Alzheimer’s disease [1, 19]. 
In line with this, Dhonukshe-Rutten and colleagues conducted a review of dietary intake pertaining to 
folate, B12 and their association with homocysteine and cardiovascular disease in Europe and used 
>350 pmol/L, 300-350 pmol/L and <300 pmol/L as favourable, moderate and marginal B12 status 
respectively [71]. Further, a 2003 review summarized evidence to suggest that a functional deficit 
may be present at levels under 332 pmol/L (400 ng/mL) and that approximately 15% of older adults 
with apparent normal B12 levels have evidence of metabolic abnormality [1]. There is evidence to 
suggest that subtle neurophysiologic changes can occur in the absence of clinical manifestations of 
B12 deficiency [59] and there is also some evidence to suggest that optimized formation of two types 
of blood cells, lymphocytes [73] and leukocytes [74], require a plasma B12 level of at least 300 
pmol/L [14]. While changing the reference range for deficiency has been controversial [59], 
subclinical deficiency has clinical relevance. Therefore subclinical deficiency (instead of 
dichotomising serum levels with normal and deficient) in addition to deficiency will be determined in 
this study. 
2.5.2 Understanding variance in B12 deficiency prevalence estimates: cut-points and 
samples 
Due to variance in the cut-point used to define deficiency and the type of sample included in the study 
(e.g., excluded at risk groups), prevalence estimates for deficiency vary widely. However, when 
context of cut-point and sample are considered together, a few trends emerge (Table 1). The studies 
that included at risk groups tended to have higher estimates compared to other studies that used 
similar cut-points. The best examples to make this point are the studies which used <148 pmol/L to 
determine deficiency. Generally, community sample estimates tended to be fairly consistent (between 
3-6% [75-77]), which was also consistent with a LTC hospital study that had no exclusion criteria for 
participants (6.7% [65]). This was contrasted with 15.4%  prevalence in a LTC-related study that 
included an at-risk group (hospitalized older adults with oral dysphagia) [38].  
The LTC-related samples tended to have higher estimates than general community samples. 
Excepting the 258 pmol/L cut-point, all estimates from LTC-related groups were either: higher than 
the community estimates, or were comparable to community estimates which used a higher cut-point 
and thus the prevalence estimate was higher. For example, LTC-related estimates of 2.5% to 35% [64, 
65, 78-80] using cut-points up to 148 pmol/L. In addition, the LTC-related samples that included at 
risk groups tended to have estimates comparable to LTC-related samples which excluded at risk 
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groups but used higher cut-points. For example, studies which used cut-points up to 148 pmol/L and 
included at risk groups yielded prevalence estimates comparable to the studies that used higher cut-
points (150-185 pmol/L) which excluded at risk groups (e.g.,  [38, 64, 79-83]). In light of this, when 
comparing prevalence estimates, it is important to consider which cut-point was used to define 
deficiency or low B12 status in addition to the sample the estimate represents. 
Limited research exists on B12 status in this LTC population. A recent scoping review was 
conducted to provide an overview of the literature on vitamin B12 in LTC [84]. The purpose of this 
review was to summarize the published research on the prevalence of vitamin B12 deficiency, 
methods of B12 treatment and the efficacy of these treatment methods in LTC. This scoping review 
identified only 19 articles with only one study being conducted in Canada [65]. Consistent with 
community prevalence estimates, these LTC relevant studies indicated a high variance in prevalence 
(between 2.6% [78] to 35% [79]). One reason for variance among LTC studies again was the use of 
different cut-points. However, when similar cut-points were used, again the context of which groups 
were included must be considered. For example, range in LTC prevalence described above is based 
on two studies with relatively similar cut-points (110 pmol/L [78] vs 116 pmol/L  [79]; 150 pg/mL 
[78] vs 157 pg/mL [79]). For these two studies, the sample was the main difference; one consisted of 
LTC hospital residents [78] (i.e., no exclusion or inclusion of more vulnerable groups) while the other 
analysed data only for those with low folate [79]. A sample comprised of those with low folate, may 
be indicative of poor nutrient status overall which may, in part, explain the wide variance of these two 
studies. This highlights the importance for consideration of diverse groups when attempting to 
determine generalizable prevalence estimates. 
2.6 How is vitamin B12 deficiency treated? 
The most common ways of treating vitamin B12 deficiency are through regular intramuscular or 
subcutaneous injections or through daily oral pills [34] of B12. Both treatments have been shown to 
be effective [37, 60, 64, 66] or equally effective at improving B12 status [1, 85, 86]. However 
treatment recommendations may vary by etiology. For example, in those with pernicious anemia, 
typical treatment is 1000 mcg/d of oral B12 each day throughout the lifecourse [11, 34]. Alternatively 
between 100-1000 mcg may be administered intramuscularly for five sequential days followed by 
lifelong monthly injections [11]. For those with food-cobalamin malabsorption, of most significance 
to the LTC population, treatment is typically a daily oral dose of B12 [34, 41]; BC Guidelines 
recommend 250 mcg/day until the underlying condition or diet is corrected [34]. For those with 
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neurologic symptoms, one to five doses of 1000 mcg are recommended through either IM or 
subcutaneous injections followed by a daily oral dose of 1000 to 2000 mcg until serum values are 
within normal range [11]. 
Less traditional methods of B12 replacement have also been successful. In a recent scoping review 
[84], three additional treatment methods (intranasal spray [40], oral nutritional supplements [51], and 
multivitamin preparations [81]) were also found to be effective for improving B12 status, but no 
studies contrasted these treatment methods. Further, other methods may exist at improving 
bioavailability of the B12 already ingested, which is a very relevant issue in older adults with a high 
prevalence for malabsorption [36]. For older adults, this could be accomplished through greater 
consumption of B12 through foods fortified with this vitamin (e.g., breakfast cereals), as the 
crystalline form does not suffer the same level of malabsorption as the food-bound form when faced 
with factors like atrophic gastritis or medications which alter gastrointestinal pH. An alternative may 
also be through generally improving gut health. One study focussed on improving food-B12 
bioavailability through increased fibre intake [53]; 30 hospital residents aged 57-68 with low total 
energy intake were included in the study. Half received a regular diet as the control group and the 
other half received oat bran containing added fibre blended into common daily meals. At baseline 
there was no significant difference between treatment groups (p>0.05); yet, after 12 weeks, the B12 
status of the treatment group was maintained while the control group B12 status decreased 
significantly (p<0.05). The authors concluded that fibre may help stabilize B12 status in this 
population. While this study is not pertinent to this thesis work, since there is some evidence that 
bioavailability of B12 can be modified, this may provide insight into complementary treatment 
methods which are acceptable to older adults and less focussed on medications. 
2.7 Why is vitamin B12 important to Long-Term Care? 
There is increasing evidence that nutritional status impacts quality of life [87], morbidity and 
mortality [88]. Among older adults (65 years or older), several nutrients including calcium, vitamin D 
and vitamin B12 [89] are of special concern due to decreased absorptive ability with age [43, 89]. 
This may be especially true in LTC where up to 70% of older adults are affected by malnutrition [51]. 
Moreover, LTC residents have a high degree of polypharmacy; of all Ontario LTC residents 65 years 
or older, more than 15% are dispensed at least 9 medications [90]. Vitamin B12 is one of the 
micronutrients most commonly affected by drug interactions due to decreased absorption [88]. This 
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further highlights the importance of monitoring vitamin B12 status especially when deficiency or 
subclinical deficiency can take on a wide range of symptoms. 
The general lack of literature on vitamin B12 prevalence in LTC indicates an opportunity for 
further work in the field. Work on vitamin B12 deficiency in LTC has the potential to impact over 
70,000 thousand residents in Ontario [91] approximately 140,000 residents in Canada [91] and 
approximately 1.4 million LTC residents in the United States [92]. Using a moderate LTC B12 
deficiency prevalence estimate of 11%, this equates to directly impacting up to 165,000 North 
Americans living in LTC who are potentially deficient. Again, monitoring B12 status is important as 
the proportion of older adults potentially affected by B12 deficiency in LTC is nontrivial. 
2.7.1 Factors potentially associated with B12 status 
Malnutrition in general, has been associated with poorer quality of life [93] and affects 20-60% of 
LTC residents [52]. For older adults living in LTC, micronutrient deficiency, specifically vitamin B12 
deficiency,  is relevant yet preventable form of malnutrition [50]. While the leading cause of B12 
deficiency is due to decreased absorptive abilities, poor intake is still a concern [88] and intake as 
determined by the RDA may not be sufficient. Risk for B12 deficiency is further exacerbated by 
additional factors including certain medications or conditions which affect absorption as outlined 
below.  
2.7.1.1 Medications 
Research suggests that the use of some medications may decrease vitamin B12 status, specifically 
proton-pump inhibitors (PPIs), H2 blockers, and use of metformin and antibiotics. PPIs are used to 
treat H. pylori infections which impacts up to 60% of older adults and increases the risk of atrophic 
gastritis [1]. There is some evidence to suggest that the use of PPIs may cause decreased 
bioavailability of B12 [1] and is associated with decreased B12 levels [40, 94]. The rationale is that 
the use of PPIs reduces the amount of hydrochloric acid in the stomach, both decreasing the ability to 
disassociate food-bound vitamin B12 from associated protein, and reducing acidity of the small 
intestine thus increasing the likelihood for bacterial overgrowth (i.e., the pH of the small intestine 
increases and becomes a more favourable environment than at a lower pH) [1]. Similarly, there is 
some evidence to suggest that H2 blockers may impact B12 status due to decreased release of IF [3]. 
With this in mind, we anticipate that residents taking PPIs or H2 blockers may be more likely to have 
lower vitamin B12 levels than those who are not.  
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Literature also suggests that metformin use may be associated with decreased B12 levels [3, 56-
58, 95]. It is thought that metformin interferes with the transport of vitamin B12 into cells through 
disruption of calcium-dependent receptor-mediated endocytosis of IF-bound-B12 [1]. There is some 
evidence to suggest that antibiotic use may be associated with decreased B12 through blocked 
absorption [3]. We anticipate that residents on metformin or antibiotics may be more likely to have 
lower B12 levels than those not taking these medications. Antibiotic and metformin use are 
anticipated to be high in LTC, with the high incidence of infections and diabetes in this segment of 
the population.  
2.7.1.2 Conditions and diseases potentially associated with deficiency 
B12 is involved in many high level processes. Literature suggests that symptoms associated with 
subclinical B12 deficiency include: cognitive decline [1, 63, 70, 96], depression [7, 15, 16, 21, 62, 63, 
97-102], and lethargy [62], all of which impact ability to perform activities of daily living. Having 
numerous diagnoses may also be associated with B12 status. Specific conditions to consider are 
hypothyroidism, depression, and dementia, the latter being prevalent in a median of 58% of in LTC 
residents [103]. 
There is some evidence to suggest that hypothyroidism may be associated with the risk of 
pernicious anemia in part due to a high prevalence of concomitant parietal cell antibodies in 33% of 
hypothyroid patients [104].A fairly recent study reported that 40% of a sample of 116 hypothyroid 
patients were vitamin B12 deficient [104]. B12 is involved in production of neurotransmitters through 
the formation of s-adenosyl methionine, a universal methyl donor, which among other reactions is 
involved in the methylation of neurotransmitters. Sometimes subclinical B12 deficiency presents as 
depression [7, 15, 16, 21, 62, 63, 97-102]. The literature is unclear on whether B12 status is 
associated with cognitive decline. While there is evidence to suggest that low serum B12 imparts an 
increased risk for Alzheimer’s disease [74], more rapid cognitive decline [1, 63, 70, 96], increased 
risk of brain atrophy [105] or more pronounced deep white matter lesions [106], others have failed to 
report any association between cognitive status and B12 levels [2, 19, 106, 107]. A potential 
confounder between the potential association of dementia and B12 status could be age. Literature 
suggests that B12 status decreases with age, in part due to reduced absorption [108].  In addition, up 
to 30% of older adults have atrophic gastritis which decreases both HCl secretion but also IF 
secretion, thus reducing the ability to absorb vitamin B12 [11] and increases the likelihood of 
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deficiency. Any research attempting to understand B12 status in LTC needs to consider these 
diagnoses and characteristics of residents.  
2.7.2 To test or not to test: Existing guidelines and recommendations for Vitamin B12  
Despite evidence of an association between B12 status and health risk factors, relatively few 
guidelines pertaining to screening or testing exist [34, 86, 109-112]; of those that do, most pertain to 
cognitive functioning or dementia [86, 109-112]. Three guidelines related to, but not specific to, older 
adults, were identified on www.guideline.gov . These guidelines from Clinical Research Centre for 
Dementia of South Korea, the European Federation of Neurological Societies, and the European 
Federation of Neurological Societies-European Neurological Society respectively pertain to diagnosis 
and evaluation of dementia [110] (2011), diagnosis and management of Alzheimer’s disease [109] 
(2010), and diagnosis and management of disorders associated with dementia [111] (2012). All of 
these guidelines recommend B12 testing  as part of laboratory testing to rule out this potential cause 
of dementia. Specific to Canadian older adults, Garcia conducted a review summarizing the evidence 
pertaining to B12, folate and homocysteine for investigation of cognitive function [112]. The review 
concluded with recommending inclusion of B12 in dementia assessment; however insufficient 
evidence of effectiveness of vitamin treatment for other forms of dementia (e.g., Alzheimer’s type) 
was available to warrant other recommendations [112]. Only one set of recommendations were found 
specific to LTC. In 2001, Smith recommended that within LTC, routine testing for B12 be completed 
in a targeted manner for those with neurologic abnormalities, cognitive impairment, macrocytic 
anemia, nonspecific symptoms including weakness and fatigue as well as those with risk factors for 
vitamin B12 deficiency [68].  
Somewhat in opposition to the above, in 2013, the Ontario Health Technology Advisory 
Committee (OHTAC) released recommendations for vitamin B12 testing and cognitive function [86]. 
These recommendations can be summarized as follows: 1) serum B12 testing should be restricted to 
those with potential macrocytic anemia or malabsorption; 2) routine testing for investigating 
dementia, cognitive impairment or based on vague presentations such as alopecia, dizziness, fatigue 
should be avoided; and 3) oral B12 is recommended for treatment instead of IM unless there is 
evidence of malabsorption [86]. Somewhere between these extremes of targeted screening in LTC 
and no screening unless macrocytic anemia or malabsorption are evident, reside the British Columbia 
guidelines (BC Guidelines) and protocols for investigating and managing vitamin B12 deficiency 
[34]. These BC Guidelines suggest that there is no indication for routine screening. However, they do 
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recommend consideration of testing for adults over 75 years of age, for those with medical or surgical 
history that may impact B12 status (e.g., inflammatory bowel disease, gastric resection), for vegans 
and for those taking H2 receptor agonists, PPIs or metformin [34]. Again a targeted approach based 
on selected risk factors, which may or may not apply to the LTC population is advocated. 
Although older adults living in LTC may be more vulnerable than those living in the community, 
there may be advantages to living in a residential setting. Despite conflicting recommendations for 
testing, the most relevant to LTC are recommendations to test for B12, at least in a targeted manner 
[68]. These recommendations, specific to LTC, may have influenced protocols for testing of vitamin 
B12, leading to potentially timely treatment for those who are deficient, as compared to older adults 
living elsewhere. It can be hypothesized that: routine screening for B12 status in LTC is a common 
practice, treatment protocols support improvement of status, and that prevalence of persons living in 
care for a period of time with a B12 deficiency is potentially lower than frail older adults living in the 
community. The BC guidelines also suggest repeat testing once after 4-6 months for those receiving 
IM or subcutaneous B12 [112], none of the other guidelines discuss monitoring of vitamin B12 status 
after initial assessment [34, 86, 109-112]. Thus, incidence of deficiency has not been addressed in this 
population limiting insight into how B12 status may change, which factors affect this change and how 
effective LTC is at addressing B12 deficiency. 
2.8 Summary 
Vitamin B12 deficiency is a potential problem in LTC that could impact a significant number of 
residents. Due to the nonspecific nature of symptoms associated with subclinical deficiency, 
prevalence of poor food intake, the high degree of polypharmacy and health conditions associated 
with poor B12 status, LTC residents are at a potentially increased risk for B12 deficiency as 
compared to older adults living in the community. There are few existing guidelines for testing and 
treating B12 deficiency directly relevant to the LTC sector, none of which provide recommendations 
on follow-up testing. In general, vitamin B12 status is a relatively unexplored field; few studies have 
addressed prevalence and of those, a lack of generalizability impedes the understanding of true B12 
deficiency prevalence; and subclinical deficiency is also unknown. In addition, incidence of B12 
deficiency has yet to be reported. Due to conflicting guidelines for testing, it is unclear as to how 
vitamin B12 status is addressed through testing and treatment within LTC. This thesis aims to begin 
to address these gaps in knowledge and practice. 
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Table 1: Summary of B12 deficiency prevalence estimates in community and LTC-related sample by cut-point and group 
Ref Sample  Inclusion/Exclusion  
Group 
Included 
110  
pmol/L 
116  
pmol/L 
125 
pmol/L 
133 
pmol/L 
148 
pmol/L 
150 
pmol/L 
153 
pmol/L 
185 
pmol/L 
221 
pmol/L 
258 
pmol/L 
[113] Community 
1/3rd most disabled women 
(African American; 
Caucasian) 
Included 
at risk 
- - - - - - - - 13.5%; 22.1% - 
[77] Community 
Veterans >65 with no 
diagnosis associated with 
B12 deficiency Normal 
- - - - 6.0% - - - 16.0% - 
[76] Community 
Free living older adults 
Framingham Normal 
- - - - 5.3% - - - - 40.0% 
[75] Community 
Free living older adults 
NHANES  (1999-2000; 
NHANES III) Normal 
- - - - 3%; 5% - - 7%; 13% - - 
[82] LTC-related 
Excluded heart disease, 
taking B12, organ or 
endocrine disease 
Excluded 
at risk 
- - - - - - 34.0% - - - 
[81] LTC-related Dementia excluded 
Excluded 
at risk - - - - - 31.0% -  - - 
[83] LTC-related 
Cancer, CVD, antiepileptic 
drugs, thyroid hormones, 
B12 supplements excluded 
Excluded 
at risk 
- - - - - - - 15.7% - - 
[80] LTC-related 
Excluded B12 deficiency, 
renal insufficiency and life 
threatening diseases 
Excluded 
at risk 
- - - 7.8% - - - - - - 
[79] LTC-related 
Psychogeriatric patients 
with low folate 
(Community; LTC) 
Included 
at risk 
- 32%; 35% - - - - - - - - 
[55] LTC-related 
use H2 blockers or PPIs; 
B12 users excluded 
Included 
at risk 
- - - - - - - - - 29.0% 
[64] LTC-related Suspected B12 deficiency 
Included 
at risk - - 17.0% - - - - - - - 
[38] LTC-related 
Hospitalized with oral 
dysphagia 
Included 
at risk - - - - 15.4% - - - - - 
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Ref Sample  Inclusion/Exclusion  
Group 
Included 
110  
pmol/L 
116  
pmol/L 
125 
pmol/L 
133 
pmol/L 
148 
pmol/L 
150 
pmol/L 
153 
pmol/L 
185 
pmol/L 
221 
pmol/L 
258 
pmol/L 
[65] LTC-related LTC hospital Normal - - - - 6.7% - - - - - 
[78] LTC-related LTC hospital Normal 2.5% - - - - - - - - - 
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Chapter 3 
Rationale and Research Questions 
3.1 Rationale 
Vitamin B12 status is a relevant topic to older adults [114] and deficiency has avoidable clinical 
ramifications, especially for those living in long-term care [115].  While classical symptoms of B12 
deficiency are either hematologic or neurologic, presentation of symptoms are not reliable as 
diagnostic tools [43] as these symptoms are not present in all cases of B12 deficiency [11]. 
Furthermore, symptoms of subclinical B12 deficiency are nonspecific; a blood test is required for B12 
status determination and as a first step towards treatment. B12 screening and treatment protocols in 
LTC have not been documented and no studies have been designed to establish vitamin B12 clinical 
and subclinical deficiency prevalence at admission or to describe follow-up incidence within this 
population. Furthermore, studies on prevalence using a cross-section of the LTC population lack 
representativeness. This thesis aims to address these knowledge gaps. 
3.2 Research questions 
The overarching aim of this research was to gain insight about the proportion of residents affected, 
what screening procedures are in place and what treatment methods are being used to address vitamin 
B12 deficiency in LTC.  
The following specific research questions were posed: 
1. What protocols and procedures are in place for testing and treatment of B12 deficiency upon 
admission and during residents’ stay in Ontario LTC residents? 
1.1. What residential covariates (e.g., ownership, geography, for-profit status) are associated with 
protocols and procedures for testing and treatment of vitamin B12 deficiency?  
2. What is the prevalence of B12 deficiency at admission for current residents of the Schlegel 
Villages? 
2.1. What is the proportion of residents receiving vitamin B12 treatment prior to their admission 
to LTC? 
2.1.1. Of those on this treatment, what is the prevalence of B12 deficiency and what is their 
mean B12 level? 
2.2. Which covariates (if any) are associated with B12 levels at admission to LTC? 
 22 
3. What is the incidence of B12 deficiency one year post-admission to the Schlegel Villages? 
3.1. Which covariates (if any) are associated with B12 levels at one year post-admission? 
To address these research questions, two studies were completed: an environmental scan involving 
interviews with directors of care from Ontario LTC home and a multi-site retrospective prevalence 
study. Results from this thesis may inform future work aimed at identification of treatment protocol 
effectiveness and future policy and intervention protocols. 
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Chapter 4 
Variability in Ontario long-term care practices for screening and 
treatment of vitamin B12 deficiency 
4.1 Overview 
BACKGROUND: Vitamin B12 deficiency impacts multiple domains (e.g., anemia, neuropathy, 
depression) and is often misdiagnosed; however it is an avoidable condition with screening and 
proactive treatment. Although prevalence in long-term care (LTC) is largely unknown, vitamin B12 
deficiency impacts up to 40% of community-living older adults. Screening and treatment practice to 
address this avoidable deficiency is also poorly described. OBJECTIVE: The primary purpose of 
this study was to describe the state of vitamin B12 screening and treatment in Ontario LTC homes. 
The secondary purpose was to investigate the impact of covariates (e.g., geography and corporate 
structure) on: (a) current policies or procedures for vitamin B12 testing upon admission to LTC; (b) 
the reported proportion of treated residents; and (c) current treatment protocols. METHODS: A 
stratified random sample of LTC homes was selected, and 45 phone interviews with the directors of 
care were completed representing 5243 residents in this cross-sectional study. A standardized 
interview schedule was used to collect data. Descriptive analyses were completed. RESULTS: Cut-
off values for determining B12 deficiency varied among homes; the most common were <156 pmol/L 
(31%), <198 pmol/L (21%) and <148 pmol/L (21%). Two thirds (30/45) of the participating sites 
routinely tested for B12 levels at admission to LTC and follow up B12 testing was completed in 88% 
(35/40) of homes, presenting a potential gap in determining the efficacy of treatment. On average 25 
± 16% of current residents were receiving vitamin B12 supplements (41/45 homes reporting). The 
most common form of treatment was regular intramuscular injections (53%) followed by daily oral 
supplements (44%). CONCLUSIONS: There is variability in practices with respect to detection and 
treatment of B12 deficiency in LTC, potentially placing residents at risk for undetected deficiency. 
Consensus is needed on cut-points for determination of deficiency in this population, as well as clear 
treatment and monitoring protocols which begins at admission to LTC. 
 
(Prepared for submission to the Canadian Journal on Aging) 
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4.2 Introduction 
Vitamin B12 has been identified as a micronutrient of interest for older adults as it is readily depleted 
by drugs [11, 43, 88], and deficiency is commonly caused by atrophic gastritis which is highly 
prevalent in this segment of the population [43, 88]. Nonspecific symptoms associated with 
subclinical B12 deficiency make diagnosis challenging and include: depression [7, 15, 62, 63, 97-101, 
116, 117], other psychiatric symptoms [62, 76, 100, 118], impaired neurotransmitter and monoamine 
synthesis [62, 116], cognitive decline or dementia [8, 15, 63, 117], increased confusion [7, 98] or 
memory problems [7, 98], balance and mobility issues due to peripheral neuropathy [14, 63, 117], and 
osteoporosis [14]. These symptoms are in addition to classic symptoms of vitamin B12 deficiency 
including macrocytic megaloblastic anemia, pernicious anemia and degeneration of the spine [14, 15, 
43, 62, 63]. Specifically, pernicious anemia affects up to 5% of older adults [43] and is caused by B12 
deficiency which further demonstrates that this micronutrient is an issue in this segment of the 
population [18, 41, 88]. One particularly vulnerable group for B12 deficiency are older adults (65 
years or older) living in LTC, where malnutrition affects up to 65% [119] of this population. Low 
micronutrient intake commonly coincides with protein-energy malnutrition and there is a significant 
potential for deficiency. Generally, older adults in LTC are more vulnerable to micronutrient 
malnutrition due to any combination of: inadequate micronutrient content of the meal resulting from 
menu planning challenges; low food intake resulting from functional impairment, slow eating, taste 
changes, poor appetite [120, 121]; and the high use of medications [90]. While decreased absorptive 
abilities is the main cause of B12 deficiency, low intake is still a concern as there may be increased 
B12 requirements for those with absorption problems [88]. 
Prevalence of B12 deficiency (or marginal status) in community-living older adults (age 65+) is 
estimated at up to 40% [16, 39, 41, 75, 77, 113, 122, 123]. Relatively few studies have reported on 
B12 deficiency prevalence in LTC; estimates outside of Canada range from 7% [65] to 34% [82] and 
only one Canadian study representing LTC exist. Prevalence of B12 deficiency in LTC is anticipated 
to be similar or potentially higher, due to challenges in eating and deficits in menu planning [124], 
since there are relatively few foods in which B12 naturally exists (i.e., only in animal products) [30]. 
Further, symptoms of vitamin B12 deficiency are subtle, nonspecific and are frequently unrecognized 
or misdiagnosed [39, 41]. This highlights the importance of regular testing; vitamin B12 deficiency 
can only be determined by blood work as the classic symptoms as such are unreliable for diagnosis 
[43]. 
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This potentially avoidable deficiency provides a potential opportunity for improving health 
outcomes if B12-related care practices are effective at addressing vitamin B12 deficiency in LTC. 
However, a gap exists in our understanding of LTC practices; detection, treatment and monitoring 
patterns of vitamin B12 status in Canadian LTC remain unknown. The purpose of this study was to 
describe the practices of Ontario LTC homes for the detection, treatment and monitoring of vitamin 
B12 status. Specifically, 
1. Does vitamin B12 screening occur at admission to LTC? 
2. What cut-points are used to diagnose a vitamin B12 deficiency?  
3. What types of vitamin B12 treatment are used in LTC? 
4. How often/does monitoring of B12 status occur in LTC?  
Secondly, do these practices vary based on characteristics of the LTC home (e.g., location, profit 
status and corporate structure)?  
4.3 Methods 
4.3.1 Study Design and Participants:  
This was a cross-sectional study with data collected through phone interviews with the directors of 
nursing (also referred to as directors of care) or an alternative knowledgeable informant from the 
long-term care home. Data were collected between August and December, 2013. 
4.3.2 Sampling and Recruitment: 
The Ontario Long Term Care Association (OLTCA) and the Ontario Association of Non-profit 
Homes and Services for Seniors (OANHSS) member listings were chosen to provide the widest and 
largest coverage of Ontario LTC homes. These listings have representation across private, municipal, 
charitable and non-profit long term care homes. OLTCA and OANHSS were selected instead of the 
Ontario Ministry of Health and Long-Term Care (MOH-LTC) public reporting site as they provided 
the necessary detailed information for stratification purposes, as well as up-to-date contact 
information for the home administrator. These combined associations’ members provide care to 
approximately 106,000 residents living in LTC in Ontario (70,000 and 36,000 from OLTCA and 
OANHSS respectively) [125, 126]. A list of all Ontario LTC homes in the OLTCA and OANHSS 
was compiled (N=651). After removal of long-term care hospitals, recently closed homes, or LTC 
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homes with 0 reported beds (n=31), the remaining 620 homes were then stratified by covariates based 
on corporate structure and geography.   
A home was classified as either for-profit (n=359) or not-for-profit (n=261) as defined by the 
OLTCA reporting website and/or OANHSS membership. It was hypothesized that for-profit homes 
may have different protocols than not-for-profit, with respect to preventative practices such as 
screening for B12 deficiency. A home was classified as either an umbrella (n=445) home or a non-
umbrella (n=175) home. Umbrella status was defined as any group of two or more homes owned or 
operated by the same company; it was hypothesized that umbrella homes may have a different 
structure that supported policy and practice implementation. A home was classified geographically 
based on the Local Health Integration Network (LHIN) in which it resides. Geographical region was 
then categorized as South-Western (n=327), Eastern (n=94), Northern (n=56) or Central Ontario 
(n=143); it was hypothesized that geographical region and density of LTC homes within a 
geographical region may impact how policy and practice are implemented particularly with respect to 
ordering of blood tests. As this was a descriptive study, a random stratified sample consisting of 
approximately 10% of these homes was desired as potential participating sites. With a goal of 
recruiting 45-60 sites, 194 homes were invited, assuming a participation rate of approximately 30%.  
Three methods of contact were used for recruitment: 1) initial hard copy letter to the LTC home 
explaining the purpose and importance of the project, 2) email to the administrator, and 3) phone call 
issued to director of care. Figure 2 provides the flowchart depicting sample recruitment and 
inclusion. Only one hard copy letter was sent to each LTC home. If, in speaking with the informant, 
they failed to receive the letter, an electronic copy was sent. If there was no response after 
approximately 2 weeks, one initial email was sent to the administrator. If after three days there was no 
response, a follow-up email was sent to the same contact. A total of 83 emails and follow-up emails 
were issued. At least two phone contact attempts were made and up to two voicemails were left for 
the director of care. If the LTC home advised on calling back later, this added to the number of 
phone-call attempts made. A total of 61 follow-up phone calls were issued in efforts to determine 
interest or schedule interviews. Once initial interest in participation was established, at least two more 
contact attempts were made to schedule and conduct the interview. Recruitment stopped when the 60 
homes (plus an anticipated 10% loss) agreed to participate. Of the 68 LTC homes initially recruited, 
45 followed through with data collection.  
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4.3.3 Data Collection: 
Interviews were completed over the phone by the first author. Informants were provided with the 
questions before hand to support completion of the interview. For missing data identified during the 
interview, at least one follow-up email or phone call was issued (n=14). Questions were developed by 
the authors based on the aims of the study around current policies or procedures for B12 testing at 
admission to LTC, the reported proportion of treated residents and treatment protocols. Some 
questions were modified to be more clear after trialling the questions with the first few homes. In 
addition, each home was asked about whether their home was aware of recently released 
recommendations on B12 testing for cognitive function by the Ontario Health Technology Advisory 
Committee [86]. 
4.3.4 Statistical Analyses: 
Due to lower participation rates across three of the four geographic regions, Eastern, Northern, and 
Central Ontario were collapsed for comparisons against South-Western Ontario. This made for a 
more equal comparison of geographic groups and also allowed for grouping of geographically high 
density versus low density LTC homes.   
Data were analysed using IBM SPSS Statistics version 21. Descriptive statistics were as follows: 
dichotomous variables were presented as the proportion of responses for a given question; continuous 
variables were presented as the mean and standard deviations. A chi-square test was conducted to 
establish whether the characteristics of participating homes differed significantly from the Ontario 
LTC population identified in the sampling frames. Chi-square or Fisher’s exact tests were conducted 
to determine whether site characteristics were associated with practices. Since LTC homes varied in 
size, the proportion of residents receiving vitamin B12 and which form of treatment were reported. A 
weighted average was calculated by summing these proportions and dividing by the total number of 
homes reporting residents receiving treatment. 
4.4 Results 
Forty-five participants/homes representing 5243 residents are included in this descriptive analysis; 
participation rate was 23%. The sample was not found to be statistically different from the sampling 
frame/population by geography, umbrella status or profit/not profit designation (χ2=2.11 (df=1), 
p>0.1, see Figure 3). Table 2 provides a summary of descriptive variables by LTC characteristic. 
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4.4.1 Detection:  
There was diversity in cut-off values used to determine B12 deficiency among the participating 
homes. The range of values used was 100-300 pmol/L. The most common cut-points to determine 
B12 deficiency were <156 pmol/L (n=12; 31%), <198 pmol/L (n=8; 21%) and <148 pmol/L (n=8; 
21%); (response to this question: 87%; 39/45). Generally, these cut-points were associated with the 
labs chosen for blood work. For example, <156 pmol/L was used to define a B12 deficiency at 
LifeLabs.  
Fifty-nine percent (26/44) of homes commented that their home currently had a B12 testing 
protocol. Almost all (44/45) of LTC homes reported that they requested a vitamin B12 test at some 
point during selected residents’ stay with the remaining 1/45 , for-profit, non-umbrella, medium sized 
home (between 75-100 beds) in Eastern Ontario reporting that they never did B12 testing, but in their 
home, 21% of residents were receiving B12 (85% on oral, 15% on IM). However, only 67% (30/45) 
of the participating sites routinely tested for B12 levels at admission of the resident to their LTC 
home. No significant differences were found on screening practices between LTC home 
characteristics for geography, for-profit status and umbrella status (p>0.20). 
4.4.2 Treatment 
Current treatment was used as a proxy for identified deficiency. One of the 41 homes reported that 
100% of residents, regardless of admission blood work, were treated. This was a not-for-profit, not-
umbrella, large home (between 150-175 beds) located in southwestern Ontario; all residents received 
monthly IM injections. Of the remaining 40 homes which reported treatment of B12 deficiency, a 
range of prevalence of residents currently receiving treatment was identified (Figure 4). Most homes 
reported having between 20-29% of their residents on vitamin B12 and 61% of homes reported that at 
least 20% of their residents were currently receiving vitamin B12 treatment(s). No significant 
differences were found between proportion of residents receiving vitamin B12 treatment and LTC 
characteristics for geography, for-profit status and umbrella status (p>0.20). 
Homes were asked to comment on treatment modality. Most homes offered more than one 
modality (38/43; 88.4%); 87.8% (36/41) of homes used oral, 97.6% (40/41) of homes use IM and 
7.3% (3/41) of homes used another form of B12 treatment (subcutaneous injections). Only 5 homes 
(11.4%) exclusively offered vitamin B12 treatment via IM injections; 36 (81.8%) offered oral and 
IM; one home (2.3%) offered oral and subcutaneous; and two homes (4.5%) offered either oral, IM or 
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subcutaneous B12 treatment. No significant differences were found between which forms of B12 
treatment therapy was offered by an LTC home and characteristics for geography, for-profit status 
and umbrella status (p>0.10). 
Homes were also asked to comment on the proportion of residents receiving each type of 
treatment modality. Of the residents receiving B12 treatment at a given LTC home on average, 53.1% 
(range (RG) 0-100%) received treatment in the form of IM B12, followed by 44.3% (RG 0-91.7%) 
through oral B12 and, 2.58% (RG 0-50%) through another form (e.g., subcutaneous B12). In terms of 
dosage, IM ranged from 500 to 1000 mcg administered either monthly, bimonthly or biweekly and 
oral doses ranged from 50 to 1200 mcg administered daily. The remaining 4.5% (2/44) received 
vitamin B12 through regular subcutaneous injections of 1000 mcg administered either monthly or 
quarterly. No significant differences were found between the proportion of residents receiving a form 
of B12 therapy at a given LTC home and LTC characteristics for geography, for-profit status and 
umbrella status (p>0.10). Reported estimates (n=31) of adherence to B12 treatment were high at 
97.4% with no significant difference across LTC characteristics (p>0.10). Several interviewees 
commented that adherence was high because administration of medications is the responsibility of 
medical staff, not the residents themselves.  
4.4.3 Monitoring 
Almost all (44/45; 97.8%) of the participating sites reported that they conduct B12 follow-up testing. 
Yet, there was no consistent procedure for frequency of follow-up tests. One out of 44 homes (2.3%) 
was not sure if their home did follow-up testing in light of providing treatment to everyone, 7/44 
(15.9%) homes did not complete follow-up B12 testing. The remaining 36/44 (81.8%) of homes 
conducted the following form of follow-up testing: annually 22/44 (50%), semi-annually 2/44 (4.5%), 
quarterly 8/44 (18.2%), monthly 1/44 (2.3%), and only at the discretion of the doctor 3/44 (6.8%). 
Among the homes that reported some form of follow-up, no significant differences were found 
between frequency of follow-up testing and LTC characteristics for geography, for-profit status and 
umbrella status (p>0.10). Only 5/43 (12%) homes were aware of OHTAC recommendations; 3/5 
reported awareness as a result of having received the questions in advance of the interview and had 
researched the recommendations. 
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4.5 Discussion 
This work demonstrates a variety of practices with respect to detection, treatment and monitoring of 
vitamin B12 status in Ontario LTC. For example, one third of LTC homes did not screen at 
admission. This could mean that residents who are highly vulnerable and potentially malnourished are 
moving into some LTC homes with an undiagnosed deficiency that can progressively impact their 
quality of life and health. Symptoms associated with an untreated B12 deficiency may also result in 
other investigations or treatments that lead to further comorbidity due to the non-specific nature of 
vitamin B12 related symptoms. Testing at admission should be a minimum standard due to: the 
increased risk of older adults, especially in the vulnerable; the low cost of a serum B12 measure; and, 
the simplicity and effectiveness of treatment. Additionally, it is possible that presentation of classic 
symptoms or symptoms associated with subclinical vitamin B12 deficiency may overlooked due to 
the general high degree of comorbidity in LTC; a blood test is the only way to confirm B12 status. 
However, it would be remiss to ignore the inherent challenges in defining screening protocols and the 
economical cost of screening. With approximately 71,000 older adults 65 years or older living in 
Ontario LTC homes [91], assuming 30% new admissions per year, and an average cost of $12.50 per 
serum B12 test [42], the cost for B12 screening using serum B12 for older adults in Ontario is 
approximately 1.2 million dollars annually (not accounting for treatment and monitoring costs). With 
this in mind, there is a need for a formal cost-benefit analysis for screening and subsequent treatment. 
While residents on treatment were commonly monitored in some way, there were no consistent 
practices noted by respondents, such as timing of the monitoring. Two contrasting examples are the 
one home (NFP, not-umbrella, 150-175 beds, in SW Ontario) who provided treatment for all residents 
regardless of admission or follow-up bloodwork levels and the one home (FP, not-umbrella, 75-100 
beds, in Eastern Ontario) who never conducted B12 testing yet reported that 21% of residents 
received B12, 85% of whom received IM. In the former case, it may be that all residents receive B12 
because it is more efficient to treat everyone than to monitor select individuals. B12 monitoring may 
have been limited to those with low B12, thus treatment of all residents avoids potential for incident 
cases of deficiency. In the latter case, it may be that this home relied exclusively on home care 
transfer paperwork and bloodwork, such as admission to hospital. Such differential follow-up 
practices may leave a treatment gap for residents and lack of routine screening post admission could 
result in the missing of an emerging vitamin B12 deficiency while living in LTC. Furthermore, poor 
care transitions to LTC could also lead to care gaps. For example, a resident may have been receiving 
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B12 treatment in the community but after a poor care transition to LTC, the resident may have been 
identified as having normal B12 levels at admission to LTC and thus did not receive continued 
required treatment. Without a follow up test to indicate whether the resident’s B12 level remained 
constant or decreased (or increased), a change in B12 level could go unnoticed, and thus deficiency 
could develop. 
The proportion of residents receiving B12 treatment could be used to roughly estimate prevalence 
of identified deficiency; however, prevalence on admission as compared to developing during a 
resident’s length of stay remains unknown. Based on the reported proportions receiving treatments 
across the sample homes, a rough estimate of B12 deficiency prevalence in Ontario LTC homes is 
approximately 20%. This estimate is consistent with prior LTC work outside of Canada which 
indicates vitamin B12 deficiency prevalence is between 7% and 34% [37, 39, 65, 82]. Future work 
needs to be aimed at an appropriately powered study with a generalizable population to accurately 
determine the prevalence of B12 deficiency on admission to LTC. Another opportunity for future 
work is to investigate the incidence of B12 deficiency after admission and during a resident’s length 
of stay within an LTC home. These studies will lay a foundation for policies around vitamin B12 
testing and treatment, as well as how to support positive care transitions. Prior work demonstrates that 
B12 deficiency in older adults does respond readily to treatment [37, 40, 51, 64, 81], potentially 
improving the quality of life, cognition and function of older adults living in long-term care.  
4.6 Strengths and Limitations 
While it is anticipated that there is some selection bias in these data as those homes that decided to 
participate are likely different in some way, one strength of this study was that the sample was found 
to not significantly differ from the population of the sampling frame in terms of geography, for-profit 
and umbrella status (χ2=2.11, p=0.15). In addition the minimum sample desired of 45 was met.  That 
said, since there was some missing data, and the sample size was less than 10% of the population, 
potentially limiting external validity. At the outset, a relatively low participation rate was anticipated, 
and borne out in the recruitment; this impacts the generalizability of results. It is anticipated that these 
selection and response biases have resulted in an underestimate of the potential problem with vitamin 
B12 in LTC. The sampling frame is a limitation of this work. Two organizations in Ontario which 
provide lists of members were available and used to stratify this sample based on key characteristics; 
yet coverage of the entire population of Ontario LTC homes was not 100%. However, random 
selection of homes to participate promotes some generalizability of findings. 
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This study contained minimal missing data due to extensive attempts for follow-up (range of 
proportion of missing data per question: 0 to 21%). Interviews were conducted by only one 
interviewer which implies good internal validity and consistency of how questions were presented. 
Finally, these results are based on the report of a knowledgeable informant in the LTC home and not 
all questions were answered by participants. To facilitate accurate responses, the questions were 
provided to the respondents before the interview. However, it is unknown how systematic these 
respondents researched their answers, such as the proportion of residents currently on B12 therapy.  
Objective measurement that can be confirmed by audit needs to be used in future research to 
understand prevalence and care practices. In spite of these limitations, this is the first comprehensive 
study to examine vitamin B12 testing protocols in Ontario. These data provide a baseline for future 
studies on the vitamin B12 status of older adults living in LTC homes. 
4.7 Conclusion 
Although two-thirds of a stratified random sample of LTC homes in Ontario reported conducting 
admission bloodwork for screening B12 deficiency, there is no consistency in the detection, treatment 
and monitoring of this potential deficiency. Lack of standardization in cut-points to diagnose 
deficiency is a significant challenge for understanding prevalence and success with treatment. Once 
these concepts are better understood, evidence may further inform policy and practices that support 
adequate vitamin B12 status in LTC residents.  
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Figure 2: Sampling framework for environmental scan. FP: for-profit, NFP: not-for-profit, UMB: 
umbrella home (i.e., at least 2 homes run by the same organization), N-UMB: not-umbrella home. 
 
Figure 3: Sample representativeness of environmental scan. 
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Figure 4: Distribution of the proportion of current residents reported receiving B12 at a given LTC 
home. 
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Table 2: Summary of B12 practices by LTC home characteristics (n=45).* 
Question 
Total across 
all homes 
% positive 
responses 
LTC Characteristics 
Geography For-Profit Status Umbrella Status 
C+N+E 
Ontario 
SW 
Ontario 
P 
value NFP FP 
P 
value Not UMB UMB 
P 
value 
Does your LTC home 
currently have a B12 testing 
protocol? (N=44) 
59.1% 
(26/44) 
n=20 
55.0% 
(11/20) 
n=24 
62.5% 
(15/24) 
n.s.d 
n=14 
57.1% 
(8/14) 
n=30 
60.0% 
(18/30) 
n.s.e 
n=12 
58.3% 
(7/12) 
n=32 
59.4% 
(19/32) 
n.s.e 
Does your LTC home test for 
B12 levels on admission? 
(N=45) 
66.7% 
(30/45) 
n=20 
65.0% 
(13/20) 
n=25 
68.0% 
(17/25) 
n.s.e 
n=14 
64.3% 
(9/14) 
n=31 
67.7% 
(21/31) 
n.s.e 
n=12 
66.7% 
(8/12) 
n=33 
66.7% 
(22/33) 
n.s.e 
At any point during a 
resident’s stay, does your LTC 
home test for vitamin B12? 
(N=45) 
97.8% 
(44/45) 
n=20 
95.0% 
(19/20) 
n=25 
100% 
(25/25) 
n.s.c 
n=14 
100% 
(14/14) 
n=31 
96.8% 
(30/31) 
n.s.e 
n=12 
91.7% 
(11/12) 
n=33 
100% 
(33/33) 
n.s.c 
Does your LTC do follow-up 
B12 measurements for those 
identified to be deficient? 
(N=40) 
85.0% 
(34/40) 
n=18 
77.8% 
(14/18) 
n=22 
90.9% 
(20/22) 
n.s.c 
n=12 
75.0% 
(9/12) 
n=28 
89.3% 
(25/28) 
n.s.c 
n=10 
70.0% 
(7/10) 
n=30 
90.0% 
(27/30) 
n.s.b 
Is your home aware of the 
recent OHTAC 
recommendations around 
vitamin B12 testing? (N=43) 
11.6% 
(5/43) 
n=18 
11.1% 
(2/18) 
n=25 
12.0% 
(3/25) 
n.s.e n=13 7.7% (1/13) 
n=30 
13.3% 
(4/30) 
n.s.e n=11 9.1% (1/11) 
n=32 
12.5% 
(4/32) 
n.s.e 
How many homes have 
between 0-25% of residents 
currently receiving vitamin 
B12 treatment? (N=41) 
65.9% 
(27/41) 
n=17 
52.9% 
(9/17) 
n=24 
75.0% 
(18/24) 
n.s.c 
n=13 
53.8% 
(7/13) 
n=28 
71.4% 
(20/28) 
n.s.c 
n=11 
63.6% 
(7/11) 
n=30 
66.7% 
(20/30) 
n.s.c 
How many homes have 
between 26-50% of residents 
currently receiving vitamin 
B12 treatment? (N=41) 
29.3% 
(12/41) 
n=17 
41.2% 
(7/17) 
n=24 
20.8% 
(5/24) 
n=13 
38.5% 
(5/13) 
n=28 
25.0% 
(7/28) 
n=11 
27.3% 
(3/11) 
n=30 
30.0% 
(9/30) 
How many homes have 
between 51-75% of residents 
currently receiving vitamin 
B12 treatment? (N=41) 
2.4% 
(1/41) 
n=17 
5.9% 
(1/17) 
n=24 
0.0% 
(0/24) 
n=13 
0.0% 
(0/13) 
n=28 
3.6% 
(1/28) 
n=11 
0.0% 
(0/11) 
n=30 
3.3% 
(1/30) 
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Question 
Total across 
all homes 
% positive 
responses 
LTC Characteristics 
Geography For-Profit Status Umbrella Status 
C+N+E 
Ontario 
SW 
Ontario 
P 
value NFP FP 
P 
value Not UMB UMB 
P 
value 
How many homes have 
between 76-100% of residents 
currently receiving vitamin 
B12 treatment? (N=41) 
2.4% 
(1/41) 
n=17 
0% 
(0/17) 
n=24 
4.2% 
(1/24) 
n=13 
7.7% 
(1/13) 
n=28 
0.0% 
(0/28) 
n=11 
9.1% 
(1/11) 
n=30 
0.0% 
(0/30) 
Of the residents receiving B12 
treatment what % of homes 
use more than 1 form of B12 
treatment (e.g., IM and 
ORAL)? (N=43) 
88.4% 
(38/43) 
n=19 
94.7% 
(18/19) 
n=24 
83.3% 
(20/24) 
n.s.c 
n=14 
85.7% 
(12/14) 
n=29 
89.7% 
(26/29) 
n.s.e 
n=12 
75.0% 
(9/12) 
n=31 
93.5% 
(29/31) 
n.s.b Of the residents receiving B12 
treatment, what % of homes 
use only 1 form of B12 
treatment (e.g., IM only)? 
(N=43) 
11.6% 
(5/43) 
n=19 
5.3% 
(1/19) 
n=24 
16.7% 
(4/24) 
n=14 
14.3% 
(2/14) 
n=29 
10.3% 
(3/29) 
n=12 
25.0% 
(3/12) 
n=31 
6.5% (2/31) 
What proportion of LTC 
homes use ORAL B12 
treatment therapy? (N=41) 
87.8% 
(36/41) 
n=17 
94.3% 
(16/17) 
n=24 
83.4% 
(20/24) 
n.s.d 
n=13 
84.6% 
(11/13) 
n=28 
89.3% 
(25/28) 
n.s.b 
n=11 
72.7% 
(8/11) 
n=30 
93.3% 
(28/30) 
n.s.b 
What proportion of LTC 
homes use IM B12 treatment 
therapy? 
(N=41) 
97.6% 
(40/41) 
n=17 
94.3% 
(16/17) 
n=24 
100% 
(24/24) 
n=13 
100% 
(13/13) 
n=28 
96.4% 
(27/28) 
n=11 
100% 
(11/11) 
n=30 
96.7% 
(29/30) 
What proportion of LTC 
homes use another form B12 
treatment therapy? 
(N=41) 
7.3% 
(3/41) 
n=17 
11.8% 
(2/17) 
n=24 
4.2% 
(1/24) 
n=13 
15.4% 
(2/13) 
n=28 
3.6% 
(1/28) 
n=11 
0% 
(0/11) 
n=30 
10% 
(3/30) 
Of the residents receiving B12 
treatment, what percent of 
residents are receiving ORAL 
B12 at your LTC home? 
(N=40) 
44.3% 
(RG 0-
91.7%) 
n=17 
40.3% 
(SD±25.3) 
n=23 
47.3% 
(SD±30.3) 
n.s.c 
 
n=13 
51.1% 
(SD±27.4) 
n=27 
41.1% 
(SD±28.4) 
n.s.c 
n=11 
43.0% 
(SD±17.9) 
n=29 
44.8% 
(SD±25.3) 
n.s.e 
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Question 
Total across 
all homes 
% positive 
responses 
LTC Characteristics 
Geography For-Profit Status Umbrella Status 
C+N+E 
Ontario 
SW 
Ontario 
P 
value NFP FP 
P 
value Not UMB UMB 
P 
value 
Of the residents receiving B12 
treatment, what percent of 
residents are receiving IM B12 
at your LTC home? (N=40) 
53.1% 
(RG 0-
100%) 
n=17 
56.5% 
(SD ±28.8) 
n=23 
50.5% 
(SD±32.2) 
n.s.d 
n=13 
43.5% 
(SD±30.2) 
n=27 
57.7% 
(SD±30.2) 
n.s.b 
n=11 
57.0% 
(SD±31.4) 
n=29 
51.6% 
(SD±28.2) 
n.s.d 
Of the residents receiving B12 
treatment, what percent 
residents are receiving another 
form of B12 supplementation 
at your LTC home? (N=40) 
2.58% 
(RG 0-50%) 
n=17 
3.1% 
(SD±9.2) 
n=23 
2.2% 
(SD±10.4) 
n.s.d 
n=13 
5.4% 
(SD±14.5) 
n=27 
1.2% 
(SD±6.4) 
ⱡn.s.c 
 
n=11 
0% (SD±0) 
n=29 
3.6%  
(SD±11.4) 
ⱡn.s.b 
 
What would you estimate the 
% treatment adherence to be? 
(N=31) 
97.4% 
(SD±4.5) 
n=14 
98.7% 
(SD± 1.82) 
n=17 
96.4% 
(SD± 5.74) 
n.s.b 
n=10 
98.3% 
(SD± 3.3) 
n=21 
97.0% 
(SD± 5.0) 
n.s.c 
n=9 
95.9% 
(SD± 5.3) 
n=22 
98.0% 
(SD± 4.1) 
n.s.c 
*Whenever expected values in cells were greater than five, the χ2 test statistic was calculated with asymptotic 2-sided significance p-value. Whenever expected 
values in cells were less than five, the exact 2-sided significance p-value from the Fisher’s Exact Test was calculated. (a=p>0.05, b=p>0.10, c=p>0.20, d=p>0.50, 
e=p>0.80). SD is the Standard Deviation of the mean. ** RG is the range. ⱡequal variances not assumed. 
 
 
Table 3: Summary of additional phone interview responses by question. 
ADDITIONAL QUESTIONS   
What is the dosage ranges for Oral? n = 29: 50 mcg/d - 1200 mcg/d 
What is the dosage ranges for IM? n = 38: 500 -1000mcg/ injection 
What form of B12 is used for Oral? (e.g., cyanocobalamin, methylcobalamin) n = 13: (cyanocobalamin > “vitamin B12”) 
What form of B12 is used for IM? (e.g., cyanocobalamin, methylcobalamin) n = 15: (all cyanocobalamin) 
At what level does your LTC home define B12 values to be "deficient"? n = 39: avg =163.9 (SD=35 RG 100, 300) 
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Chapter 5 
Vitamin B12 deficiency prevalence in older adults living in Ontario 
long-term care homes 
5.1 Overview 
BACKGROUND: Undernutrition is prevalent in long-term care (LTC) and can lead to mortality and 
morbidity, yet it may be amenable to intervention. Vitamin B12 is a micronutrient of which 
deficiency is relatively common in older adults and is treatable. As a first step towards improving B12 
status, prevalence of deficiency and how it is currently being treated in the LTC setting needs to be 
understood. Small, ungeneralizable samples reported to date provide a limited perspective on this 
issue. PURPOSE: The primary aim of this study was to report prevalence of B12 deficiency at 
admission to Ontario LTC homes and incidence at one year post admission. The secondary aim was 
to explore associations between admission B12 status/level and resident admission characteristics in 
an attempt to understand if there is a subset of new admissions to LTC for whom vitamin B12 levels 
may be low. METHODS: This was a retrospective prevalence study representing 8 sites across 
south-western Ontario within one LTC organization. Eligibility criteria for inclusion of charts: 
resident was 65 years or older at admission and had admission bloodwork including B12 levels. 
Random proportionate sampling was used to identify resident charts for inclusion with replacements 
as necessary. 1005 chart reviews were conducted to obtain a total of 412 that were eligible. Only 142 
of these charts had bloodwork at one year. Covariates of interest included: basic demographics, B12 
supplementation, medications, diagnoses, functional independence, cognitive performance, and 
nutrition. RESULTS: Prevalence of B12 deficiency (<156 pmol/L) was 13.8% (range 4.1-27.1% 
across sites) at admission to LTC. Yet, only 47.6% of residents had normal B12 (>300 pmol/L) at 
admission, with the remaining residents categorized as subclinical. B12 supplementation use prior to 
admission was significantly associated with a better admission B12 status (p<0.001). There was a 
significantly higher proportion of B12 supplementation at admission in those with dementia 
compared to those without (p<0.01). Number of medications at admission was negatively associated 
with B12 level. Incidence of new B12 deficiency cases was 4%. CONCLUSIONS: The present 
multisite study, with a large sample, provides a better understanding than previous work on B12 
status at admission to LTC. More than 50% of residents had B12 levels <300pmol/L indicating poor 
B12 status in this LTC sample. Supplementation use was significantly associated with better B12 
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status at admission to LTC. Future work should use prospective methods to identify treatment 
protocol effectiveness as well as incident B12 deficiency to inform future policy and intervention 
protocols.  
(Prepared for submission to the Journal of Applied Physiology, Nutrition and Metabolism) 
5.2 Introduction 
Optimizing independence and quality of life is increasingly important with age, especially among the 
most vulnerable older adults living in long-term care (LTC) [127]. Research in LTC suggests risk 
undernutrition is prevalent at up to 65% [119], and can lead to mortality and morbidity [128]. Yet, 
some undernutrition in this setting may be amenable to intervention [129, 130]. Undernutrition is 
commonly thought of as protein-energy malnutrition, and although micronutrient malnutrition also 
exists in older adults, it is poorly studied in LTC [50, 121]. A specific micronutrient malnutrition is 
B12 deficiency; it is relatively common in community living older adults, but is treatable [11, 37, 41].   
As a first step towards improving vitamin B12 status in LTC, understanding prevalence of B12 
deficiency, characteristics of those who are at risk, and how B12 status changes over time is required. 
While, B12 deficiency prevalence estimates have been established in the community-living older 
adult ranging from 3-43% [11, 15, 16, 41, 75-77, 113], little work has been done in LTC. Variation in 
this prevalence is due to differences in cut-points used to define deficiency, as well as either inclusion 
or exclusion of population subgroups at greater risk for deficiency (e.g., frail older adults) [113]. Lack 
of prevalence data in LTC may be partially attributable to: difficulty in gaining access to LTC homes, 
or determination of prevalence impeded by variance in defining “deficiency”. The confidential nature 
of resident files and the LTC population considered to be a vulnerable group have also been barriers 
to gaining access for anyone outside the residents’ circle of care [131].  
The potentially high prevalence in the community, especially of physically and cognitively 
dependent older adults [113] suggests that screening for B12 status at admission to LTC is a 
potentially worthwhile process. Additionally, persons receiving transitional care are generally more 
vulnerable due to: the stress and anxiety of relocation [132]; the potential for breakdown in 
communication on medication and other treatments that are not incorporated into the resident’s care 
plan post admission [133]; and change in primary physician caring for the resident. As a result, B12 
treatment started in the community (especially intramuscular modality (IM) which is normally 
provided on a monthly basis, typically in a doctor’s office), may be overlooked and lost as a 
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component of the resident’s care plan. To date in LTC, there have been no studies that report on 
status of B12 deficiency at admission or incidence of developing this deficiency post admission. 
While understanding prevalence at admission to LTC is a first step for determining if standardized 
screening and treatment protocols are required, understanding incidence provides insight into how 
B12 status changes with age, and other factors and over time while living in residence.  
Only four studies of the LTC population conducted in the past decade have reported B12 
deficiency prevalence [39, 65, 80, 82] with only one, small study (n=75) based in Canada [65]. None 
of these studies considered the question of prevalence of deficiency on admission or incidence within 
one year of admission to LTC. The Canadian study took place in one LTC/chronic care hospital in 
Guelph, Ontario [65]. The primary research objective of this study was to determine prevalence of 
vitamin deficiencies (including B12) in LTC. Secondary objectives were to determine if associations 
existed between B12 status and cognitive function, vitamin supplementation, and medications 
impacting gastric acid [65]. With a sample size of 75, which was potentially biased as 35% refused 
consent, this study was likely insufficiently powered to detect these associations, and is unlikely to be 
representative of LTC homes in Ontario. The prevalence of B12 deficiency in this sample was 7%, 
using a cut-point for deficiency of <148 pmol/L (<200 pg/mL) [65]. 
The three non-Canadian studies found a range in prevalence from 8- 34% [39, 80, 82]. A study in 
one LTC home of male veterans in Taiwan [80] was designed to explore the association between 
vitamin B12 supplement use and cognitive function and depressive symptoms [80]. Although this was 
a large study (n=419), it was not designed to answer the question of prevalence and exclusion criteria 
may have biased the sample beyond the single gender inclusion. The prevalence of B12 deficiency in 
this sample was 8% using a cut-point for deficiency of <133 pmo/L (<180 pg/mL) [80]. A study in 
Jordan compared young adults to older adults living at home or in one of five LTC homes [82]. The 
primary research objective was to determine the prevalence of hyperhomocysteinemia and folate and 
B12 deficiencies [82]. Multiple comparison groups and several covariates including medical history, 
smoking habits, and lifestyle habits were measured. However, it was unclear how participants were 
selected and the sample size of each group was relatively small (77 young adults, 169 community 
living older adults, 38 older adults living in LTC). In addition, those with “coronary heart disease, 
systemic illness, serious-organ disease, endocrine disease, and those currently taking vitamins” (pg. 
410) were excluded [82] which limits the generalizability of these results. The prevalence of B12 
deficiency in this sample was 34% in both LTC and community living older adults and 9% in young 
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adults using a cut-point for deficiency of <154 pmol/L (<208pg/mL). The most recent study was from 
2012 and took place across 5 LTC homes in Australia [39]. The primary objective was to determine 
the prevalence of undiagnosed B12 deficiency in Australian LTC homes. Strengths of this study 
include random sampling across more than one site, with a high representation from the sample 
population (35% of residents were included). With a sample size of 130, the study was well powered 
to detect prevalence of B12 deficiency. However, as the study included all current residents, it is 
unclear if B12 deficiency developed during stay or prior to admission to the home. The prevalence of 
B12 deficiency in this sample was 14% using a cut-point for deficiency of <150 pmol/L (<203 
pg/mL) [39]. One study reported on B12 deficiency incidence in a sample of Alzheimer’s disease 
patients recruited from a health science centre [134]. Over three years, incidence was identified in 
7.3% of Alzheimer’s patients, however this study lacks generalizability as those with dementia other 
than Alzheimer’s were excluded in addition to those who used B12 supplements; residence was not 
considered [134]. 
It is apparent that there is limited evidence on prevalence to support LTC testing and treatment 
protocols for vitamin B12 deficiency. Despite this lack of evidence, general recommendations for 
B12 testing and treatment have been released [86, 112] and current practices for testing and treatment 
in Ontario LTC homes have been reported for the first time [67]. Specifically 67% (30/45) of LTC 
homes in Ontario test for B12 status on admission to the home. With regard to treatment, in the 
literature, there has been a change in understanding of the effectiveness of typical treatment methods 
(i.e., oral therapy vs. intramuscular therapy) which is consistent with the recommendations, however 
it is unclear how this translates into practice [37, 41, 64, 135]. Additionally, recommendations for 
screening and treatment are not specific to LTC. Further work is required to help establish such 
recommendations. For example, what is the effectiveness of treatment methods for older adults 
leading up to admission to LTC and during residence, and who is at risk for B12 deficiency upon 
entry into an LTC home. This knowledge would help to determine treatment modalities as well as if 
screening should be in place and if it should be targeted to specific subgroups of the population or for 
all new admissions. Several medications and diagnoses have been associated with decreasing B12 
levels including: metformin [3, 56-58, 95], antacids such as proton-pump inhibitors [40, 94] and H2 
blockers [3], antibiotics [3], hypothyroidism [104], gastrointestinal (GI) conditions increasing the risk 
for food-B12 malabsorption [2, 54], mood and mood related disorders [7, 15, 16, 21, 62, 63, 97-102], 
dementia (including Alzheimer’s-type dementia (ATD)) [74] and cognitive decline [1, 63, 70, 96], as 
well as cardiovascular disease [4, 23-26] and elevated levels of homocysteine [27]. B12 status may be 
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associated with the performance of daily activities as well as nutrition related covariates such as 
weight changes and could thus influence the quality of life of older adults living in LTC. All of these 
are potential means of identifying targeted subgroups that should be screened on a routine basis, yet 
data is lacking in a single study to support such a targeted approach. 
5.3 Purpose 
The primary aims of this retrospective study were to determine the prevalence of vitamin B12 
deficiency at admission to LTC across several sites and to describe the sample characteristics of 
persons identified to be deficient. Secondary research aims were to explore: how admission B12 
status and B12 levels are associated with covariates of interest (e.g., supplementation use at 
admission, BMI, number of diagnoses, number of medications, type of medications, presence of 
mood related disorders, PPI use, etc.); if B12 status changed one year post admission; and if this 
change in status was associated with these covariates of interest.  
5.4 Methods 
5.4.1 Sample and Design 
This was a retrospective prevalence study which took place in originally  9 of 11 (8 completed) of the 
Schlegel Villages (SVs). The SVs are a family-run group of continuum-of-care homes across Ontario 
(Windsor to Barrie) offering independent living (in retirement) to long-term care. This organization 
has an organization-wide policy for admission bloodwork to be completed for each resident and B12 
testing is included in the work-up, making this study feasible. As a result, policies and procedures are 
similar across the organization and due to geographical differences, residents across multiple homes 
are diverse and potentially more representative of all Ontario LTC residents. Prevalence of B12 
deficiency was determined using admission bloodwork. Due to differences in the cut-points for B12 
deficiency defined by labs contracted by a home, a common B12 level was needed to determine 
potential B12 deficiency. Recent work by the authors involved an environmental scan of Ontario LTC 
home practices pertaining to vitamin B12 testing and treatment in 45 LTC homes across Ontario. 
Results also indicated that there was no consensus to define vitamin B12 deficiency; cut-points used 
were directed by the lab at which the blood samples were analysed and ranged between 100 pmol/L to 
300 pmol/L. The most common cut-point used for defining vitamin B12 deficiency was less than 156 
pmol/L in 31% of homes (12/45) followed by less than 198 pmol/L in 21% and less than 148 pmol/L 
in 21% of LTC homes. Based on this work, the cut-point at which to define vitamin B12 deficiency in 
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this study was defined as less than 156 pmol/L [41]. In addition, the cut-point at which to define 
normal vitamin B12 was a serum value greater than 300 pmol/L. The rationale for this definition 
comes from the authors’ prior work in which this cut-point was found to be a conceivable level; 
values in between “deficient” and “normal” were defined as subclinical (156 pmol/L – 300 
pmol/L).The subset of 9 LTC homes included in this study were limited to those within two hours of 
the University of Waterloo to promote feasibility with data collection.  
5.4.2 Sample Size and Sampling Frame 
A complete listing of all current residents in each of the 9 LTCs included in the sample was provided 
(n=1355) and this value was used to estimate the required sample size to determine prevalence of B12 
deficiency. A prevalence as low as 5% with 95% confidence could be determined with a sample of 
size of 341 [136]. After data collection began, it was evident that the practices with respect to 
detection of B12 status at admission at one site were different than that of the other 8. To reduce bias, 
this site was removed from the sampling frame. In addition, one neighbourhood (unit) was on an 
infectious outbreak precaution at the time of the chart review; the number of charts to be collected 
from this site remained constant but were only collected from the remaining neighbourhoods. The 
total population of older adults was thus recalculated, yielding n=1061. Thus the final required 
sample size to estimate a prevalence of 5% with 95% confidence with a finite population correction 
was identified to be 319.    
Charts were only available for extraction of current residents. Eligible residents were those in the 
LTC portion of the home who were over the age of 65 years (on average 88% of residents; n=1183) 
and for whom there was admission bloodwork. Random proportionate sampling was used to identify 
which preliminarily eligible resident charts (i.e., > 65 years) were selected for data extraction. 
Bloodwork was only available on the physical chart in hard copy reports. Based on this random 
sampling, residents chart reviews were conducted for each neighbourhood and home until the 
predetermined proportionate number based on the home size and total sample size of the population 
was reached. Eligibility was confirmed at each site based on those for whom there was admission 
bloodwork; if a resident was selected randomly and did not have admission B12 bloodwork, this 
resident was replaced with the next one on the random number list. Of the 1061 residents 65 years of 
age and over at admission, 535 residents were excluded due to missing or inability to locate 
admission bloodwork. One resident’s chart which was randomly selected was removed as the resident 
had previously opted out of research projects, and was thus excluded and replaced. The total number 
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of charts reviewed and included was 413. One resident was removed from analysis as their data from 
the MDS report corresponded to a different resident and thus the total number of residents data 
included in this prevalence estimate for admission bloodwork was 412 (see Appendix A). 
5.4.3 Description of Extracted Variables 
A data extraction from was created, reviewed by the research team and tested in 30 charts to ensure 
that all relevant information could be extracted. Except for serum vitamin B12 level at admission, 
missing values were permissible for any covariate as this did not affect determination of prevalence; 
therefore, proportions of missing data varied across covariates. Chart reviews were conducted by the 
first author and data were extracted as follows: basic demographics (e.g., sex, age, length of stay, 
marital status, etc.), serum vitamin B12 levels on admission to LTC and at first annual bloodwork if 
available, and the lab-based determination of deficiency; number of medications, prescribed 
medications at admission; number of diagnoses with note of cardiovascular disease, dementia, 
Alzheimer’s-type dementia (ATD), hypothyroidism, gastro-intestinal (GI) conditions, mood 
conditions and selected variables from the Minimum Data Set (MDS), as described below.   
Due to charting differences among sites and over time (as some residents had been residents for 
several years), the following process was used to extract a complete data collection and ensure 
consistency in values extracted. Admission lab results were reviewed and the value was recorded 
including the lab-specific cut-point used for defining B12 deficiency. In addition, first annual lab 
results were reviewed wherever possible to extract B12 level at 1 year post admission to LTC. Next, 
the new admission information form for basic demographics, medications and diagnoses was 
reviewed. When admission medications were unavailable on this form, nursing home admission 
documents were checked. If duplicates of medications were listed (e.g., 1 medication taken more than 
once per day or different doses at different times), these were counted as one medication. Medications 
for over the counter skin lotions (e.g., barrier, penaten) were not counted towards total number of 
admission medications.  Those residents receiving B12 treatment therapy (resident receiving 
treatment: Yes/No and form: intramuscular injections or oral) prior to admission to the home were 
noted. If no admission form was available to determine diagnoses, the first post admission printout 
from the resident medical tracking software (GoldCare) was used. Diagnoses were counted only 
according to what was written in the admission diagnoses section. It was noted that there was 
inconsistency in this history with respect to prior surgeries; when surgeries were included as part of 
patient history, they were counted as diagnoses. 
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Antibiotic use was recorded as “yes” if resident was prescribed oral antibiotics or an ointment 
containing antibiotics. Metformin use was recorded as “yes” if a resident was prescribed metformin. 
PPI, H2 blocker and antacid use was recorded as “yes” if a resident was prescribed a type of PPI, H2 
blocker or antacid respectively. The presence of cardiovascular disease was recorded as “yes” if a 
resident had a history of stroke, CAD, peripheral vascular disease or atrial fibrillation. The presence 
of dementia was recorded as “yes” if a resident was diagnosed with dementia, mixed dementia, mild 
dementia, or diagnosed with a probable dementia; diagnosis of cognitive decline was not included in 
this definition of dementia. The presence of GI conditions was recorded as “yes” if the resident had a 
diagnosis of gastroesophageal reflux disease (GERD) or were prescribed a PPI, H2 blocker or 
antacid. The presence of hypothyroidism or thyroid dysfunction not including hyperthyroidism was 
recorded as “yes” if the resident had a diagnosis of hypothyroidism. The presence of 
mood/psychiatric illness or mood related disorders was recorded as “yes” if the resident had a 
diagnosis of depression, anxiety, or schizophrenia. If diagnoses were missing from the new admission 
information form or nursing home admission documents, admission diagnoses and number of 
diagnoses were regarded as “missing”. 
Several variables from the MDS at admission were extracted. For a description on relevant 
subsections, see Appendix B. A RAI-MDS 2.0 report was generated by the information specialist at 
the Schlegel Villages for all residents within an available timeframe (2010 – 2014). This timeframe 
captured admission data for over 95% of included residents; 19 residents moved in prior to 2010 and 
these data were thus not available. Cognitive performance scale (CPS) score corresponds closely with 
the Mini-Mental State Examination [137]; score values range from 0 (intact) to 6 (very severe 
impairment). The ADL-short (ADL-s) scores range from 0-16 and ADL-long (ADL-l) scores range 
from 0-28 where a higher score indicates greater difficulty in performing daily activities [138] were 
also extracted. The report also contained data on resident’s weight, height, nutritional problems and 
weight change, although this data was missing from one site for the year 2010. Body Mass Index 
(BMI) was calculated by dividing weight (kg) by the square of the height (m) from the MDS data. 
Upon computation, three biologically implausible values were removed in accordance with prior 
work [139], assuming the data were improperly entered. 
5.4.4 Statistical Methods 
Data were entered into Excel and imported into SPSS version 23.0 for statistical analyses. 
Frequencies, proportions and descriptive analyses as well as graphing of variables were used to clean 
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the data. ANOVA were conducted to determine the association between B12 values and categorical 
variables. Where appropriate, the Tukey B test was used to establish between group differences [140]. 
Chi-square tests were used to determine associations between categorical variables. Paired t tests 
were conducted for all admission and first annual bloodwork comparisons. The level of significance 
used was p≤0.01 to account for multiple tests. A two-proportion z-test was used to establish whether 
the proportionate samples were significantly different than the planned sample proportions using a 
level of significance of p<0.05 [141]. 
5.5 Results 
5.5.1 Subject Characteristics 
The proportion of charts included from each village did not differ significantly from the planned 
proportion of residents to be included to ensure a representative sample (p>0.05). However the 
number of alternates needed to reach sufficient inclusion from each village ranged between 4 and 99 
with a mean of 67 and a median of 72. See Appendix A for a flow diagram for this study. 
Of the 412 reviewed charts, 286 (69%) of residents were female. The mean age of this sample at 
admission was 83 (±7yrs) with a range from 65 to 101. The average, standard deviation and mode for 
length of stay from admission to date of data collection was 22 ± 20 months and 9 months 
respectively. The most recent admission was 1 month prior to data collection and the longest length of 
stay prior to data collection was 11.2 years. Marital status in this sample was as follows: 48% 
widowed, 39% married, 6% divorced, 5% single or never married, and 2% were separated. The mean 
number of admitting diagnoses was 6.05 (SD 2.73) ranging from 1 to 18. The following key 
conditions had the following prevalence: diabetes (21.6%), cardiovascular disease (38.0%), GI 
conditions (28.1%), hypothyroidism (20.2%) mood or psychiatric disorders (57.7%), dementia 
(49.5%), and Alzheimer’s type dementia (17.0%). When dementia and ADT were considered 
together, 66.1% of the sample was affected.  
The mean number of medications at admission for this sample was 10 (SD 4.5) with a range from 
0-28. In terms of medication use related to GI conditions, 26.3% of residents were taking proton 
pump inhibitors, 1.5% of residents were taking H2 blockers, and 2.7% of residents were taking 
antacids. Metformin was used by 10.1% of residents and antibiotics were used by 6.2% of residents. 
At admission, 26.0% of residents were receiving vitamin B12 treatment. Of these, 80.7% received 
oral B12, 15.9% IM injections and 3.4% received both oral and IM B12 treatment. Of the residents 
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receiving oral B12, 97.3% received oral B12 treatment daily with the remaining 2.7% receiving B12 
twice daily. Dose of oral B12 treatment ranged from 100 to 1250 mcg; the most common dose was 
1000 mcg (60.0%); the dose for four residents was missing. Of the residents receiving IM B12, 93.8% 
of residents received 1000 mcg while the remaining 6.3% of residents received 300 mcg; the dose for 
one resident was missing. Frequency for IM B12 was most commonly monthly (82.4%) followed by 
quarterly (11.8%), and every two months (5.9%). 
At admission, 46.2% of the sample was cognitively impaired (i.e., CPS score of >3); the mean 
CPS score was 2.46 (SD=1.47) with a mode of 3 indicating that on average, residents were 
moderately cognitively impaired. The breakdown for residents’ cognitive status is as follows: 12.5% 
cognitively intact (CPS=0), 10.1% borderline intact (CPS=1), 25.1% mild impairment (CPS=2), 
37.0% moderate impairment (CPS=3), 5.5% moderate severe impairment (CPS=4), 6.1% severe 
impairment (CPS=5), and 3.7% very severe impairment (CPS=6). At admission the mean ADL-s and 
ADL-l scores were 6.60 (SD 4.24) and 12.69 (SD 7.64) respectively. Residents’ scores ranged from 0 
to 16 on the ADL-s and from 0 to 28 on the ADL-l indicating a high degree of variability in terms of 
physical functioning. 
In terms of nutritional status, nutritional problems and weight change and BMI were extracted. 
Within the past 7 day period, 4.6% of residents complained about the taste of many foods, 1.0% of 
residents had regular or repetitive complaints about hunger, 27.7% of residents left 25% or more of 
food uneaten at most meals and 68.9% of residents had no evidence to suggest nutritional problems. 
Weight loss of 5% or more in the last 30 days or 10% or more in the last 180 days was observed in 
5.8% of the sample, while weight change was recorded as unknown on MDS in 8.6% of the sample. 
Similarly, a weight gain of 5% or more in the last 30 days or 10% or more in the last 180 days was 
observed in 6.6% and was unknown in 8.6% of the sample. After the removal of three inconceivable 
values, the average BMI in this sample was 28.18 (SD 6.58) with values ranging from 13.22 to 60.59. 
When BMI was grouped according to low (BMI<20), normal (20≤BMI≤30) and high (BMI>30) 
ranges, 6.7% of residents had a low BMI, 58.1% had a normal BMI, and 35.2% had a high BMI. 
5.5.2 Prevalence of B12 Deficiency, Covariates, Treatment and One-Year Status  
The mean serum B12 level at admission was 358.3 ± 229.3 pmol/L and overall prevalence of B12 
deficiency was 13.8% (57/412) using the definition of less than 156 pmol/L. Prevalence of subclinical 
deficiency as defined as serum B12 level less than 300 pmol/L at admission, was 38.3% (158/412) 
while 47.6% (197/412) of residents had a normal B12 status (>300 pmol/L) at admission to their LTC 
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home. While prevalence of B12 deficiency within a given home ranged from 4.1% to 27.1%; these 
differences were not significant (p>0.01). All villages had proportions of residents with normal 
admission B12 status less than 56%. Using cut-points defined by the various labs (deficient 
<148,110,107; subclinical: 148-220, 110-150, 107-133; normal: >220, 150, 133) yielded variable 
deficiency prevalence estimates of 11.4%, 2.7%, and 1.7% respectively. Figure 5 provides the 
distribution of residents’ B12 levels at admission with the cut-points for deficiency from the lab and 
as defined in this study, this illustrates how different cut-points drives variable prevalence estimates.  
Table 4 and 5 provide a summary of results associating B12 status on admission with covariates 
of interest. Vitamin B12 supplementation use at admission to LTC was significantly associated with 
higher admission serum B12 (p<0.001; χ2=60.784 (df=2)). A significantly smaller proportion of 
residents receiving B12 at admission had deficient (2.3% vs 18.4%) or subclinical status (13.6% vs 
45.6%) than those not receiving B12 at admission thus, a significantly larger proportion of residents 
receiving B12 at admission had normal admission B12 status compared to those not receiving B12 
(84.1% vs 36.0%). Number of medications was significantly associated with admission B12 (p<0.01; 
F=6.019 (df=2,299)). Those with B12 deficient status (<156 pmol/L) at admission were, on average, 
receiving significantly fewer medications (mean=8.5 medications) than those with normal B12 status 
(mean=10.8 medications). There was no significant difference however, when subclinical B12 was 
compared to either B12 deficient or normal B12 status at admission. No other covariates were 
statistically significantly associated with B12 status.  
The type of B12 supplementation method at admission approached significance with B12 status 
(p=0.012; F=11.620). Table 6 provides a summary of results associating B12 supplementation use at 
admission with covariates of interest. In terms of oral-B12-prescribed residents, there was a higher 
proportion of normal (90% vs 57%) and a lower proportion of subclinical (8.5% vs 35.7%) and 
deficient (1.4% vs 7.1%) serum B12 than those who received IM B12.Significant associations were 
found between B12 supplementation at admission and presence of dementia (p<0.01; χ2 
(df=1)=12.028) and having either dementia or ATD (p<0.01; χ2 (df=1)=9.547). However, ATD alone 
was not significantly associated with B12 supplementation at admission to LTC (p>0.8; χ2 
(df=1)=0.097). 
Only 40% of included charts (163/412) had first annual bloodwork recorded, and as a result, 
efficacy of treatment post identification of deficiency at admission could not be determined and 
associations between resident characteristics and change in B12 status will not be presented. 
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Descriptive analyses on change in status in this subsample are as follows (see Table 7). Within this 
subsample, residents’ B12 status was significantly improved at first annual bloodwork compared to 
admission (p<0.001; F=25.6). Specifically, the majority of residents initially with vitamin B12 
deficiency with year one data (n=16) had improved B12 status after 1 year (75%); 25% of initially 
deficient residents improved to subclinical deficiency, while 50% improved to normal status after 1 
year. Of the residents initially in the subclinical deficiency category for B12 status with year one data 
(n=64), the majority of residents maintained this status at one year (56.3%); 35.9% of residents 
improved their status to “normal” and 7.8% of residents initially subclinical moved to a deficient 
state. Of the residents initially with normal B12 status with year one data (n=62), the majority of 
residents maintained this normal status (74.2%), 24.2% worsened to subclinical deficiency and 1.6% 
worsened to deficient status. Based on this subsample, incidence for worsened B12 status within this 
LTC sample at one-year was 14.8% (21/142); 4.2% to deficiency (6/142), and 10.6% subclinical 
deficiency (15/142). 
5.6 Discussion 
The overall prevalence of B12 deficiency at admission to these eight LTC homes was found to be 
14% ranging from 4.1% to 27%. This range of estimates is within that of both community estimates 
(3-43%) [11, 15, 16, 39, 41, 75-77, 113] and the few studies conducted in LTC (7-34%) [39, 65, 80, 
82]. The variation in prevalence across the eight sites demonstrates the importance of assessing 
multiple sites to determine a more representative estimate of prevalence. Among these LTC-related 
studies, similar cut-points to define B12 deficiency were used (<148 pmol/L [65], <133 pmol/L [80, 
142], <150 pmol/L [39], <154 pmol/L [82]) which simplifies comparison of prevalence estimates. 
Higher cut-points have also been used (e.g., <185 pmol/L [83], <258 pmol/L [40]) which translates to 
a greater proportion of the sample defined as deficient and fewer residents missed who may benefit 
from treatment. Conversely, a lower-cut-point (e.g., <74 pmol/L [142, 143], <116 pmol/L [79], <125 
pmol/L [64]) results in a smaller proportion of the sample identified as having deficiency. Pertaining 
to this study, labs primarily used one of three cut-points (148 pmol/L, 110 pmol/L or 107 pmol/L) 
yielding lower prevalence estimates (11.4%, 2.7% and 1.7% respectively) than the 156 pmol/L used 
in this study. This likely affected treatment that was instituted, although this was not investigated, as 
it is anticipated that physicians would respond to a deficient result provided by the lab documentation.   
Classically, presence of anemia has been used to diagnose B12 deficiency as it was thought 
progression of deficiency moved from hematologic to neurologic problems [11]. However these 
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symptoms are sometimes non-existent; more recent reports have described neurologic changes in the 
absence of hematologic changes [11]. Neurologic changes are present in most clinically deficient 
persons (75%-90%) and in up to 33% of these cases, is the only symptom present [11]. Furthermore, 
there is some evidence to suggest that nonspecific symptoms associated with subclinical B12 
deficiency can be present even at normal serum levels [1, 11] as tissues are depleted of B12 to 
maintain serum levels. This latter point highlights the importance of considering the cut-point used to 
define deficiency in prevalence studies and makes a case for considering subclinical deficiency as a 
treatable state. In this present work, when subclinical deficiency (156 pmol/L < B12 < 300 pmol/L) 
was considered, an additional 38% of residents were affected. This means that more than half (52%) 
of residents have less than an adequate B12 status at admission to LTC. This is similar to previous 
estimates of inadequate, but not solely deficient, B12 status in LTC (45% [39], 41% [65] and 61% 
[82]). Vitamin B12 status is thus a relevant form of malnutrition which needs to be considered in LTC 
populations and addressed with appropriate interventions. These data provide evidence in support of 
using oral B12 supplements over IM for older adults living in the community as there was a higher 
proportion of those with normal status and lower proportion of those with subclinical and deficient 
status for those using oral; whether this remains true after transition to LTC is unclear. It could be 
hypothesised that this may speak to an access to care issue as community-dwelling older adults may 
have a difficult time getting to their physicians office for IM treatment and thus result in missed 
doses. These data on prevalence of deficiency and sub-clinical deficiency suggest that screening for 
B12 on admission is a relevant and appropriate practice for LTC in Canada. 
Several intervention studies including a subgroup from LTC exist, many commenting on treatment 
effectiveness. While a handful of these additional studies also report on prevalence, inclusion or 
exclusion criteria were targeted at specific conditions [64, 66, 81] or medication use [40, 143] which 
would either overestimate or underestimate true prevalence. For example, there is evidence to suggest 
that PPI use increases the risk of reduced B12 levels [1, 40, 94] by decreasing the amount of 
hydrochloric acid of the stomach required to break B12 apart from food-bound sources [1]. In one 
study investigating associations between PPI use and B12 status [40] prevalence was 47%. 
Nevertheless for the purpose of describing effectiveness of treatment, these studies have merit. 
Treatment methods in these studies included: IM injections [66], oral pills [64], a comparison of oral 
and IM treatment [37], multivitamin supplementation use [81], liquid nutritional supplement fortified 
with B12 [51], and nasal spray [40]. All formats significantly improved B12 levels [37, 40, 51, 64, 
81] or B12 associated biomarkers [66]. This suggests that the LTC resident‘s B12 status is amenable 
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to treatment. This is consistent with the present study as those receiving vitamin B12 therapy prior to 
admission had a significantly lower proportion of deficient B12 status’ at admission to LTC (18% vs 
2%) (p<0.001; χ2=60.784 (df=2)) and a significantly higher mean serum B12 level (538 (SD 259) vs. 
291 (SD 172)) when compared to those not supplemented at admission (p<0.001; F=-8.298 (df=115)). 
In addition, when comparing treatment type prior to admission with admission B12 status, a 
significantly larger proportion of residents receiving oral B12 had normal B12 status (90% vs 57%) 
and a significantly smaller proportion had deficient (1% vs 7%) and subclinical (9% vs 36%) statuses 
compared to those receiving IM (p=0.006; F=0.045). This provides evidence to suggest that using 
oral B12 therapy and moving away from IM to treat B12 deficiency is feasible and effective and is 
consistent with other studies [37, 41, 86, 135]. Whether this remains true for older adults after 
admission to LTC remains unknown. One study comparing effectiveness of IM to oral 
supplementation in older adults indicated that while both were effective, IM was more effective [37].  
A significant association was found between B12 status at admission and a few of the resident 
characteristics. Use of fewer medications was associated with lower serum B12 at admission and a 
deficient status. This was an unanticipated finding based on the prior literature which suggests that 
comorbidities and some drug classes are associated with B12 deficiency. It could be hypothesized that 
number of medications was confounded by dementia status. An exploratory association identified that 
having dementia or ATD was significantly associated with taking fewer of medications (p<0.001). In 
addition, a recent study reviewing the degree of polypharmacy in all residents in LTC homes of 
Ontario, revealed this same association between dementia and medication use [90]. Thus, the 
association between number of medications and B12 status is likely confounded by dementia status. 
This finding may also be spurious as an association was not seen with subclinical deficiency. 
Similar to evidence suggesting that PPI use may lower B12, other antacids (e.g., H2 blockers) and 
antibiotics may also interfere with absorption or uptake of vitamin B12 [3]. In this present study, a 
very small proportion of residents were prescribed these medications; (antibiotics 6%; H2 blocker 2% 
and antacids 3%). Thus, the proportion of those taking these medications in addition to having poor 
B12 status at admission is even smaller. Similarly 49% and 66% of this sample was affected by mood 
or mood related disorders and dementia (including Alzheimer’s-type dementia) therefore there was a 
low degree of variability in these covariates. This study was powered to detect a prevalence of B12 
deficiency at admission of 5% with β=0.2; all other aims were secondary and more exploratory in 
nature. Thus, null findings regarding associations with rare covariates or covariates expressing low 
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variability may have been due to a type II error. Further work specifically sampling based on these 
covariates is required to determine if suspected associations between these covariates occur in LTC 
populations. Regardless, at this time, these data do not support targeted screening for B12 deficiency 
in users of these medications.  
There was a significantly higher proportion of B12 supplementation in those with dementia 
compared to those without (35% vs 18%) and in those when dementia and ATD were considered 
together (32% vs 16%) (p<0.01). However the proportion of B12 supplementation use in those with 
ATD compared to those without (25% vs 27%) was not significant (p>0.8). This may be indicative of 
different care practices between those with ATD and other forms of dementia. Recommendations 
from 2007 for B12 testing in the work-up of dementia suggest that B12 testing should be conducted 
in those with suspected dementia or cognitive decline and that those with low B12 should be treated 
with B12 therapy [112]. However, it is noted that these recommendations may not be applicable to 
those with early-onset dementia including early-onset familial Alzheimer’s disease [112]. This may 
explain in part why supplementation use was significantly associated with dementia status considered 
alone or with ATD, but not in ATD status alone. In 2013, the Ontario Health Technology Advisory 
Committee (OHTAC) released recommendations for B12 and cognitive function recommending 
against serum B12 testing when investigating potential dementia or cognitive impairment [86]. This 
study needs to be repeated at a later time to determine if this recommendation changes the current 
practice of diagnostic work-up and treatment of B12 deficiency in persons with dementia, as 
evidenced in this study.  
Two thirds of the sample did not have readily accessible first annual bloodwork and thus the 
subset with available data was potentially biased. Therefore, the efficacy of treatment post 
identification of deficiency in this sample cannot be determined. Despite the bias in this subsample 
for which first annual bloodwork was found, changes in B12 status have clinical significance. 
Specifically, 25% (4/16) of those initially deficient continued to have deficiency at one-year, but the 
majority of those found to be deficient at admission had improved by this time point. Of concern, 
15% of the sample had worsened B12 status after 1 year in LTC as compared to admission, which 
indicates, for the first time, that incidence of B12 deficiency is also relevant to this population. This 
further demonstrates the value and necessity of not only screening and treating, but also of monitoring 
B12 status on a routine basis in LTC. Due to the concern about bias, resident covariates were not 
explored to see if there were any associations with change in status post admission. Prospective 
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research needs to be conducted to determine these potential associations and what characteristics 
describe a subset of residents that do not respond to treatment. 
5.7 Strengths and Limitations 
A key strength is the eight sites included in this study resulting in a large sample with potentially 
greater diversity than previously reported LTC research. At this organization, the same blood testing 
protocol has been used for over 10 years which eliminates any potential for recency bias, which is a 
significant challenge with retrospective studies of this nature. This study also used random sampling 
and had excellent representation of eligible residents (i.e., residents aged 65 or older at admission to 
LTC). Specifically, the sample represented 37% of the total eligible population and between 31% and 
43% of eligible residents at each of the eight sites. This was the first study to report on incidence of 
vitamin B12 deficiency providing a point for comparison for future studies designed to specifically 
address incidence and associated covariates. 
This study collected data across one organization in one province of Canada which is a limitation 
as it may not be generalizable to other organizations or countries. It is anticipated that results are 
consistent with other LTC homes in south-western Ontario. The sample was drawn from this region 
and there is no bias in admission to homes based on demographic status of residents; all receive the 
same process for placement through the Community Care Access Centres in this province and have 
equal access with respect to key demographics and diagnoses that could influence B12 status. 
Another limitation to this study is that different sites handled resident information and charted data 
differently yielding some missing values; between four and 99 alternates were needed to meet the 
number of chart reviews containing complete admission B12 bloodwork at each of the sites. As a 
result, in some sites almost all charts were reviewed to determine an eligible sample, demonstrating 
the challenge of missing data with retrospective chart reviews. A final limitation was the high 
proportion of missing data on the first annual follow up. The subsample with this data was likely 
biased. This also resulted in relatively few completed data points to determine a change in vitamin 
B12 status and thus the exploratory research question concerning resident characteristics that could 
influence treatment efficacy could not be addressed. Yet, this is the first study to report on how B12 
status changes over the first year of residence in LTC and as such does add to the field.   
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5.8 Conclusions 
The prevalence of vitamin B12 deficiency at admission to eight LTC homes across one organization 
in Ontario was determined to be 14%. More than 50% of residents had vitamin B12 levels under 300 
pmol/L indicating poor vitamin B12 status overall in this LTC sample. It could be argued that this 
prevalence of subclinical/deficient status warrants screening or treating at admission for all LTC 
residents. Furthermore, resident characteristics (excepting number of medications) were not 
associated with status, indicating that targeting a subset of residents at admission for screening is an 
inappropriate strategy at this point for detecting deficiency. Of the subsample with follow-up B12 
measures at one year, B12 status was significantly improved for 75% of initially deficient residents, 
however 15% of those with an initial subclinical or normal B12 status worsened. Better admission 
B12 status and admission B12 levels were significantly associated with supplementation prior to 
admission. Future work to inform policy and intervention protocols should use prospective methods 
focusing on fidelity to treatment protocols, as well as to determine incident B12 deficiency in LTC 
and characteristics of residents that result in these outcomes. 
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Figure 5: Distribution of serum B12 levels at admission to LTC with lab cut-points (red) and author defined cut-point (black).
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Table 4: Association between B12 status (deficient, subclinical, normal) and covariates. 
Characteristic Total Sample % (n) Category Deficient Subclinical Normal 
Sex 69.4% (286/412) Female 12.2% (35) 38.8% (111) 49.0% (140) Male 17.5% (22) 37.3% (47) 45.2% (57) 
Marital status (married) 38.5% (129/335) Yes 14.7% (19) 40.3% (52) 45.0% (58) No 16.0% (33) 35.9% (74) 48.1% (99) 
Taking B12 supplements 
at admission** 26.0% (88/338) 
Yes 2.3% (2) 13.6% (12) 84.1% (74) 
No 18.4% (46) 45.6% (114) 36.0% (90) 
Form of B12 supplements 
at admission ** 26.0% (88/338) 
Oral* 1.4% (1) 8.5% (6) 90.1% (64) 
IM* 7.1% (1) 35.7% (5) 57.1% (8) 
Oral + IM 0.0% (0) 33.3% (1) 66.7% (2) 
None 18.4% (46) 45.6% (114) 36.0% (90) 
Hypothyroidism 20.2% (74/366) 
Yes 12.2% (9) 31.1% (23) 56.8% (42) 
No 14.0% (41) 40.4% (118) 45.5% (133) 
Metformin use 10.1% (34/338) Yes 17.6% (6) 35.3% (12) 47.1% (16) No 13.8% (42) 37.5% (114) 48.7% (148) 
Antibiotics 6.2% (21/338) Yes 4.8% (1) 33.3% (7) 61.9% (19) No 14.8% (47) 37.5% (119) 47.6% (151) 
CVD 38.0% (139/366) 
Yes 12.2% (17) 43.9% (61) 43.9% (61) 
No 14.5% (33) 35.2% (80) 50.2% (114) 
GI conditions 28.1% (103/366) Yes 13.6% (14) 38.8% (40) 47.6% (49) No 13.7% (36) 38.4% (101) 47.9% (126) 
Antacid use 2.7% (9/338) Yes 22.2% (2) 22.2% (2) 55.6% (5) No 14.0% (46) 37.7% (124) 48.3% (159) 
PPI use 26.3% (89/338) Yes 11.2% (10) 40.4% (36) 48.3% (43) No 15.3% (38) 36.1% (90) 48.6% (121) 
H2 blocker use  1.5% (5/338) Yes 20.0% (1) 60.0% (3) 20.0% (1) No 14.1% (47) 36.9% (123) 48.9% (163) 
Mood & mood related 
disorders 57.7% (211/366) 
Yes 10.9% (23) 39.3% (83) 49.8% (105) 
No 17.4% (27) 37.4% (58) 45.2% (70) 
Dementia 49.5% (181/366) Yes 14.9% (27) 35.4% (64) 49.7% (90) No 12.4% (23) 41.6% (77) 45.9% (85) 
Alzheimer’s 19.1% (70/366) Yes 11.4% (8) 40.0% (28) 48.6% (34) No 14.2% (42) 38.2% (113) 47.6% (141) 
Dementia or Alzheimer’s 66.1% (242/366) Yes 14.0% (34) 36.8% (89) 49.2% (119) No 12.9% (16) 41.9% (52) 45.2% (56) 
Categorical CPS [0,1,2 vs 
3,4,5,6] 47.7% (156/327) 
Yes 16.0% (25) 39.1% (61) 44.9% (70) 
No 10.5% (18) 35.1% (60) 54.4% (93) 
Weight change – K3a 
Weight loss 5.8% (20/347) 
Yes 20.0% (4) 40.0% (8) 40.0% (8) 
No 13.5% (40) 38.0% (113) 48.5% (144) 
Unknown 13.3% (4) 36.7% (11) 50.0% (15) 
Weight change – K3b 
Weight gain 6.6% (23/347) 
Yes 4.3% (1) 47.8% (11) 47.8% (11) 
No 14.6% (43) 37.4% (110) 48.0% (141) 
Unknown 13.3% (4) 36.7% (11) 50.0% (15) 
Nutritional problems – 
K4a complains about taste 
of foods 
4.6% (16/347) 
Yes 18.8% (3) 37.5% (6) 43.8% (7) 
No 13.6% (45) 38.1% (126) 48.3% (160) 
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Characteristic Total Sample % (n) Category Deficient Subclinical Normal 
Nutritional problems – 
K4b regular or repetitive 
complaints of hunger 
0.9% (3/347) 
Yes 33.3% (1) 66.7% (2) 0.0% (0) 
No 13.7% (47) 37.8% (130) 48.5% (167) 
Nutritional problems – 
K4c Leave 25% or more 
of food uneaten at most 
meals 
27.7% (96/347) 
Yes 14.6% (14) 39.6% (38) 45.8% (44) 
No 13.5% (34) 37.5% (94) 49.0% (123) 
Nutritional problems – 
K4d None of the above 68.9% (239/347) 
Yes 13.0% (31) 37.2% (89) 49.8% (119) 
No 15.7% (17) 39.8% (43) 44.4% (48) 
B12 deficiency across 
Villages 13.8% (57/412) 
Village1 25.8% (8) 25.8% (8) 48.4% (15) 
Village2 4.1% (3) 44.6% (33) 51.4% (38) 
Village3 12.9% (8) 38.7% (24) 48.4% (30) 
Village4 7.5% (3) 42.5% (17) 50.0% (20) 
Village5 27.1% (13) 31.3% (15) 41.7% (20) 
Village6 7.4% (5) 36.8% (25) 55.9% (38) 
Village7 21.1% (12) 40.4% (23) 38.6% (22) 
Village8 15.6% (5) 40.6% (13) 43.8% (14) 
B12 status by lab cut-points (deficient; normal) 
(412) 
<148; >220 11.4% (47) 20.6% (85) 68.0% (280) 
<110; >150 2.7% (11) 9.7% (40) 87.6% (361) 
<107; >133 1.7% (7) 5.3% (22) 93.0% (383) 
** significantly different p<0.01; * indicates that significance is maintained, p<0.01 upon comparison between 
these two treatment methods. 
 
Table 5: Association between admission B12 status (deficient, subclinical, normal) and covariates.* 
Characteristic (n) Mean ± SD  Deficient (n) Subclinical (n) Normal (n) 
Age (yrs) (n=412) 83.1 ± 7.1  84.4 ± 7.4 (57) 83.3 ± 6.4 (158) 82.5 ± 7.5 (197) 
ADL-s (n=327) 6.6 ± 4.2 6.6 ± 3.3 (43) 6.3 ± 4.1 (121) 6.9 ± 4.8 (163) 
ADL-l (n=327) 12.7 ± 7.6  12.6 ± 6.4 (43) 12.2 ± 7.7 (121) 13.1 ± 7.9 (163) 
Number of diagnoses 
(n=366) 
6.1 ± 2.7  5.7 ± 3.3 (50) 6.0 ± 2.6 (141) 6.2 ± 2.7 (175) 
Number of 
medications** 
(n=338) 
10.0 ± 4.5  8.5 ± 4.8** (48) 9.5 ± 4.2 (126) 10.8 ± 4.4** (164) 
Length of stay (mo) 
(n=412) 
21.8 ± 20.3  16.7 ± 21.7 (57) 24.3 ± 19.7 (158) 21.2 ± 20.2 (197) 
Categorical BMI  BMI ≤ 19 Normal BMI BMI ≥ 30 
Admission B12 
(pmol/L) (n=344) 
359.5 ± 225.6  376.6 ± 310.1 (23) 339.3 ± 201.1 (200) 389.7 ± 243.0 (121) 
**significantly different (p<0.01) * For all ANOVA analyses, Tukey B post-hoc analyses were conducted to 
report means and significance of difference between groups 
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Table 6: Association between B12 supplement use at admission and covariates. 
Characteristic Total Sample 
% (n) 
Category No Admission 
B12 
Supplement 
Admission B12 
Supplement 
Sex 67.5% (228/338) Female 76.3% (174) 23.7% (54) Male 69.1% (76) 30.9% (34) 
Marital status (married?) 40.9% (115/281) Yes 73.9% (85) 26.1% (30) 
No 77.1% (128) 22.9% (38) 
Hypothyroidism 21.8% (70/321) Yes 70.0% (49) 30.0% (21) 
No 74.9% (188) 25.1% (63) 
Metformin use 10.1% (34/338) Yes 64.7% (22) 35.3% (12) 
No 75.0% (228) 25.0% (76) 
Antibiotics 6.2% (21/338) Yes 66.7% (14) 33.3% (7) 
No 74.4% (236) 25.6% (81) 
CVD 38.0% (122/321) Yes 77.9% (95) 22.1% (27) 
No 71.4% (142) 28.6% (57) 
GI conditions 30.5% (98/321) Yes 75.5% (74) 24.5% (24) 
No 73.1% (163) 26.9% (60) 
Antacid use 2.7% (9/338) Yes 66.7% (6) 33.3% (3) 
No 74.2% (244) 25.8% (85) 
PPI use 26.3% (89/338) Yes 77.5% (69) 22.5% (20) 
No 72.7% (181) 27.3% (68) 
H2 blocker use  1.5% (5/338) Yes 80.0% (4) 20.0% (1) 
No 73.9% (246) 26.1% (87) 
Mood & mood related disorders 61.7% (198/321) Yes 70.7% (140) 29.3% (58) 
No 78.9% (97) 21.1% (26) 
Dementia** 49.2% (158/321) Yes 65.2% (103) 34.8% (55) 
No 82.2% (134) 17.8% (29) 
Alzheimer’s 19.0% (61/321) Yes 75.4% (46) 24.6% (15) 
No 73.5% (191) 26.5% (69) 
Dementia or Alzheimer’s** 66.0% (212/321) Yes 68.4% (145) 31.6% (67) 
No 84.4% (92) 15.6% (17) 
Categorical CPS [0,1,2 vs 3,4,5,6] 47.0% (133/283) Yes 73.7% (98) 26.3% (35) 
No 72.7% (109) 27.3% (41) 
Weight change – K3a Weight loss 6.3% (19/300) Yes 68.4% (13) 31.6% (6) 
No 74.8% (193) 25.2% (65) 
Unknown 73.9% (17) 26.1% (6) 
Weight change – K3b Weight gain 5.3% (16/300) Yes 50.0% (8) 50.0% (8) 
No 75.9% (198) 24.1% (63) 
Unknown 73.9% (17) 26.1% (6) 
Nutritional problems – K4a 
complains about taste of foods 
4.7% (14/300) Yes 78.6% (11) 21.4% (3) 
No 74.1% (212) 25.9% (74) 
Nutritional problems – K4b 
regular or repetitive complaints of 
hunger 
0.7% (2/300) Yes 100.0% (2) 0.0% (0) 
No 74.2% (221) 25.8% (77) 
Nutritional problems – K4c Leave 27.0% (81/300) Yes 75.3% (61) 24.7% (20) 
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Characteristic Total Sample 
% (n) 
Category No Admission 
B12 
Supplement 
Admission B12 
Supplement 
25% or more of food uneaten at 
most meals. 
No 74.0% (162) 26.0% (57) 
 
Nutritional problems – K4d None 
of the above 
69.7% (209/300) Yes 73.7% (154) 26.3% (55) 
No 75.8% (69) 24.2% (22) 
B12 status at admission** Deficient 
14.2% (48/338) 
Deficient 95.8% (46) 4.2% (2) 
Subclinical 90.5% (114) 9.5% (12) 
Normal 54.9% (90) 45.1% (74) 
B12 status at first annual 
bloodwork** 
Deficient 
7.9% (9/114) 
Deficient 100.0% (9) 0% (0) 
Subclinical 89.1% (41) 10.9% (5) 
Normal 62.7% (37) 37.3% (22) 
**p<0.01 
 
 
Table 7: Proportion of residents with improved (green), maintained (yellow) of worsened (red) B12 
status at first annual bloodwork (n=125). (p<0.001). 
 
 Year 1 Status  
(% from baseline status) 
% of year 1 status 
 
  Deficient Subclinical Normal Total 
B
as
el
in
e 
St
at
us
 
Deficient:  
B12 < 156 pmol/L 
4 
(25.0%) 
40.0% 
4 
(25.0%) 
7.3% 
8 
(50.0%) 
10.4% 
16 
(100% deficientbaseline) 
Subclinical: 
156 ≤ B12 ≤ 300 pmol/L 
5 
(7.8%) 
50.0% 
36 
(56.3%) 
65.5% 
23 
(35.9%) 
29.9% 
64 
(100% subclinicalbaseline) 
Normal: 
>300 pmol/L 
1 
(1.6%) 
10.0% 
15 
(24.2%) 
27.3% 
46 
(74.2%) 
59.7% 
62 
(100% normalbaseline) 
 Total 10 55 77 142 
      
  Proportion improved 35/142 (24.6%)   
  Proportion maintained 86/142 (60.6%)   
  Proportion worsened 21/142 (14.8%)   
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Chapter 6 
Discussion – Bringing it all together 
The purpose of this thesis was threefold: to describe which protocols are in place for LTC testing and 
treatment of B12 deficiency and which institutional covariates are associated with these protocols; to 
establish the prevalence of B12 deficiency at admission to LTC and association with resident 
covariates of interest; and to describe, for the first time, the incidence of B12 deficiency at one year-
post admission to LTC. Key findings from this work include: no significant association was found 
between LTC testing and treatment protocols and geography, for-profit status or organizational 
structure; 67% of LTC homes conduct B12 testing at admission to LTC and 85% of homes report 
follow-up testing in deficient residents. In addition, 14% of residents were identified as B12 deficient 
at admission to LTC and B12 supplementation was significantly associated with better admission B12 
status; yet, 96% of deficient residents were not receiving B12 supplements at admission. Lastly, at 
one year post-admission, B12 status was improved as prevalence of deficiency was reduced to 8% 
however, the incidence of new deficiency within this timeframe was 4%. The following discussion 
will be focused on issues that should be considered for screening, treatment and monitoring of B12 
status in LTC, as well as methodological issues that need to be considered when conducting similar 
work in the future. Finally, preliminary recommendations based on the findings of this thesis are 
offered.  
6.1 The importance of screening 
Using a cut-point of <156 pmol/L to define B12 deficiency within the Schlegel Villages, the 
prevalence was 14% ranging between 4 and 27% across eight sites. This prevalence falls within the 
reported estimated for both community dwelling older adults (3-43%) [11, 15, 16, 39, 41, 75-77, 113] 
as well as samples within LTC (7-34%) [39, 65, 80, 82]. This result provides evidence to suggest that 
a significant proportion of residents are affected by B12 deficiency, and that it can be as high as one 
in every four residents in selected sites/residents. Since classic manifestations may or may not be 
present in B12 deficiency cases and subclinical deficiency symptoms are multifaceted, vitamin B12 
admission screening is necessary to establish B12 status. This coupled with the prevalence, suggests 
that protocols for screening at admission to LTC should be instituted. Despite a lack of current 
standardized protocols or recommendations specific to LTC, the environmental scan identified that 
two-thirds of sampled homes were routinely screening for B12 deficiency at admission. It is unclear 
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from this analysis why this screening has been instituted and so highly implemented, considering that 
guidelines specific to LTC are relatively absent, and do not specifically address the issue of admission 
screening. This does however demonstrate that a screening strategy at admission is an acceptable 
practice. To fully reach 100% coverage with screening, recommendations specific to LTC still need 
to be published and disseminated. These need to be based on evidence, such as this thesis, which 
describe the prevalence and incidence of B12 deficiency at and during admission, but also requires 
further evidence to demonstrate the cost-benefit of a screening protocol that is followed with 
treatment and monitoring practices.  
The next question that arises is if targeted or blanket screening should be instituted in LTC. In the 
environmental scan (Chapter 4), screening was completed for all residents if screening was done at 
admission. Results from the prevalence study (Chapter 5) suggest that targeted screening is 
inappropriate at this point, given the null findings between B12 status and a variety of resident 
characteristics (e.g. PPI use) at admission. Covariates chosen for this analysis had some basis in the 
literature, but failed to be significantly associated in this substantial sample. Prior work often focused 
on selected samples and populations [37, 39, 65, 78, 80, 82, 83], which may have led to some of these 
characteristics being considered as potential risks for B12 deficiency. Thus, if a screening protocol is 
administered, the evidence from this thesis indicates that it should be for all LTC residents at 
admission and not targeted for certain conditions or medication use.  
Both wide variance for prevalence estimates in addition to economical valuation likely influenced 
the OHTAC’s general recommendation for restriction of screening to those with anemia or 
malabsorption and their recommendation against investigating B12 status in persons who exhibit 
dementia and/or cognitive impairment (or alopecia, dizziness, and fatigue) [86]. Although this 
guideline is counter to those from geriatric and LTC experts [109-111], OHTAC did not limit these 
recommendations to younger adults or only community living older adults. OHTAC assessed the 
burden of illness based on the reported prevalence of vitamin B12-related anemia in the general 
population, which was estimated at 2% [86]. This estimate is inappropriate for several reasons. First, 
B12 deficiency may be present in the absence of hematologic manifestations [11, 59]; up to 90% of 
B12 deficiency cases present in the form of neurologic abnormalities and in 25% of these cases, 
neurologic symptoms are the only symptom [1, 2, 4, 11]. Thus, the burden of illness estimated at 2% 
is not representative of the majority of B12 deficiency cases. Second, there is a general lack of 
evidence (i.e., mixed findings) on prevalence of B12 deficiency with relation to outcome measures 
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upon which to base broad recommendations. Third, there are even fewer studies specific to the LTC 
population to guide recommendations. Finally, the prevalence in older adults living in the community 
has been documented to be as high as 43% [11, 15, 16, 39, 41, 75-77, 113] which indicates that this 
segment of the population is an especially vulnerable group to B12 deficiency. Those being admitted 
to LTC are in an even more vulnerable nutritional, functional and cognitive state, necessitating 
consideration of these factors when setting recommendations for screening. Thus, the OHTAC 
guideline needs to be critiqued more fully and revisited to consider exclusion of LTC residents.  
As noted in this thesis, variation exists in prevalence among LTC sites (including treatment in the 
environmental scan, which was considered a proxy for prevalence of deficiency). This is not only due 
to the variability in cut-points used by labs to determine deficiency, as seen in both the environmental 
scan and prevalence study, but also the natural variation in residents being admitted to LTC homes. 
Thus, this thesis adds to the prior evidence that there is considerable variation in prevalence, 
corroborating some of the reasoning upon which the OHTAC recommendations were made. 
However, this prevalence study was one of the largest for LTC and the environmental scan at 45 
homes represented 5243 Ontario LTC residents. Considering the greater representativeness of these 
two studies than prior work, the overall average prevalence results from both studies (14% prevalence 
study; 25% environmental scan) support the need for screening at admission to LTC.  
While there is evidence that screening at admission is likely appropriate, it would be remiss to 
ignore the inherent challenges in defining screening protocols and the economical cost of screening. 
With approximately 71,000 older adults 65 years or older living in Ontario LTC homes [91], 
assuming 30% new admissions per year, and an average cost of $12.50 per serum B12 test [42], the 
cost for B12 screening using serum B12 for older adults in Ontario is approximately $1.2 million 
dollars annually (not accounting for treatment and monitoring costs). With this in mind, there is a 
need for a formal cost-benefit analysis for screening and subsequent treatment. In 2001, one such 
analysis was conducted in the US with regard to vitamin therapy to lower homocysteine levels for 
coronary heart disease prevention [144]. While this analysis was not specific to older adults as it 
included adults aged 35 through 84, it concluded that by screening and supplementing men aged 45 or 
older with 1 mg folic acid and 500 mcg vitamin B12 daily, that it would save more than $2 billion 
USD over 10 years through primary and secondary prevention of coronary heart disease incidents 
[144]. Thus, there are potential savings associated with screening and a formal cost-benefit analysis is 
needed for an estimated quantification of savings. Another consideration is blanket treatment of LTC 
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residents, as seen in one of the homes of the environmental scan. This potential will be discussed 
further below.  
Determination of B12 status is more complicated than the decision to screen. Consistent with the 
literature, different cut-points have been used to define deficiency which greatly impacts prevalence 
estimates. This was evidenced through both studies included in this thesis, with estimates varying 
based on the cut-point used by the lab. However, standardization of cut-points at the lab level is 
impractical, as different labs use different equipment each yielding different specificity and 
sensitivities [3, 4]. Furthermore, serum B12 tests are imperfect as they may yield falsely high or 
falsely low values [3, 4]. To address this, an additional biomarker specific to tissue level B12 status 
(e.g., MMA) would be beneficial for determination of B12 deficiency. Yet this would impart 
additional costs presenting a barrier for wide-spread use. There may be merit to using a higher cut-
point for potentially identifying subclinical cases. While using a higher cut-point to identify a larger 
proportion of individuals to be treated would likely imply prevention of development to deficiency, it 
would also impart added costs as treatment would be more wide-spread. Thus, the issue of 
inconsistency in cut-point use for defining B12 deficiency also impacts treatment and presents 
another ongoing challenge.  
6.2 How to treat B12 deficiency 
Based on the environmental scan as well as the prevalence study, the most common forms of vitamin 
B12 treatment are through intramuscular injections and oral pills. In the prevalence study, B12 
treatment prior to admission was significantly associated with a better B12 status at admission to 
LTC. This provides evidence to suggest that efficacy of treatment looks promising as the prevalence 
of deficiency in those not receiving B12 supplements at admission was significantly higher than those 
who were (p<0.01). However, even a small proportion (2%) of those receiving supplements had 
deficient admission B12 status, which highlights the importance of establishing efficacy of treatment 
and potentially different doses for those resistant to improved status. While those receiving 
supplementation had better B12 status, the form of treatment may be an important factor.  
OHTAC recommends that oral B12 be used unless there is evidence for malabsorption, as both 
treatments have been shown to be effective [37, 60, 64, 66] or equally effective at improving B12 
status [1, 85, 86]. The environmental scan, conducted at the same time as the OHTAC 
recommendations were released, indicated that 44% of residents received B12 in the form of oral 
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supplements, while 53% received intramuscular injections and the remaining 3% received 
subcutaneous injections. This suggests that practitioners providing care within LTC homes in Ontario 
were not implementing this current recommendation as they were generally unaware of these 
recommendations as evidenced by the environmental scan. Further work should be conducted to 
identify why prescribing patterns for B12 are not consistent with the evidence on efficacy. However, 
with time these proportions may change in light of the recommendations released by OHTAC and 
others on the equivocal effectiveness and ease of administration of oral supplements. Based on the 
prevalence study, at the Schlegel Villages 81% of residents receiving B12 received oral supplements, 
16% receive IM and the remaining 3% receive a combination of both. One interesting finding from 
the prevalence study was that on admission to LTC, 90% of those on oral supplements had normal 
admission B12 status compared to 57% of those on IM and only 1% of those on oral B12 had 
deficient B12 status compared to 7% of those on IM. Based on these findings, oral supplementation 
appears to be more effective than IM for vulnerable older adults who are eligible for LTC. It can be 
hypothesized that physically and/or cognitively impaired older adults living in the community may 
have challenges attaining IM injections, which are typically conducted in a physician’s office, 
affecting its efficacy.  
Economically, from a health care perspective, oral B12 is also advantageous as it requires fewer 
physician visits, but oral B12 is not covered by the Ontario Drug Benefit Program (ODBP) [86]. This 
translates to an out-of-pocket expense, which, for some older adults, may be too burdensome. As 
well, dosing when left in the hands of the older adult could be subject to error, either intentional or 
unintentional. As a result, monitoring of B12 status when oral treatment is used, is required to ensure 
compliance. Compliance, however, is regarded as a non-issue in LTC since medications are 
administered by health care professionals. 
Dose of treatment varies between oral therapy and parenteral (IM or subcutaneous). For oral 
therapy, larger doses are required at an increased frequency (e.g., daily) as this method of treatment 
relies primarily on passive diffusion, the minor absorptive pathway in which approximately 1% of 
oral dose is uptaken [2, 11, 18]. Guidelines suggest oral doses of 125-500 mcg daily for prophylactic 
treatment and maintenance [145], 250-500 mcg daily for those with food-cobalamin malabsorption 
[34, 145] and 1000 mcg daily for those with pernicious anemia [11, 34]. The majority of these 
suggestions are consistent with what was observed in this study, where residents on oral B12 therapy 
received 50-1200 mcg daily (environmental scan) or 100-1250 mcg daily (prevalence study). In 
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contrast, injections of B12 bypass the absorption process altogether and the B12 is deposited directly 
into tissue. As a result, the frequency of IM B12 therapy is reduced. Guidelines suggest a monthly 
administration of 1000 mcg of B12 via intramuscular injection for those with pernicious anemia [11, 
34] or with neurological symptoms in which subcutaneous injections may alternatively be 
administered [34]. The environmental scan described IM therapy of 500-1000 mcg administered 
monthly, every two months or biweekly; the prevalence study reported 300 or 1000 mcg administered 
either monthly, quarterly or every two months. Discrepancies between the limited existing guidelines 
and what is observed in practice may be indicative of increased sensitivity of physicians to the issue 
of B12 status in LTC and using their better judgement to manage treatment on a case-by-case basis. 
Training physicians on appropriate dosing and an update on the evidence of treatment modalities and 
effectiveness may improve treatment of B12 deficiency as a relevant issue to older adults and may be 
a strategy to increase consistency of B12 treatment regimens.  
Alternatively, given time constraints implicit in LTC, blanket treatment may be suitable for both 
treatment and prevention of vitamin B12 deficiency. In the environmental scan, in one LTC home 
treatment was provided to all residents regardless of admission B12 status. As a result of this 
treatment, this home reported that all residents were within their lab-defined normal range (198-615 
pmol/L). Safety is an important consideration; while no reported risks are associated with high B12 
intake and there is no defined tolerable upper limit [36], this lack of evidence was based on healthy 
individuals thus feasibility is contingent on favourable results from further research specific to older 
adults and excess from supplementation. Modality may also dictate feasibility for blanket treatment as 
IM B12 is but oral B12 is not covered by the Ontario ODBP [86]. A cost-benefit analysis considering 
cost from the health care perspective if oral B12 were to be added to the ODBP and from the resident 
perspective would be useful to inform feasibility. Using an estimated cost $0.08 for 500 mcg B12 per 
resident per day, a cost estimate (not including reductions in costs associated with screening, 
monitoring and clinician visits) would equate to approximately $29 per resident per year or $2.1 
million CAD annually for blanket treatment of all Ontario older adults living in LTC. 
6.3 Is monitoring in LTC required? 
Beyond the issue of compliance, monitoring B12 status is necessary as evidenced by the prevalence 
study in which deficiency was present, even among those receiving B12 supplements at admission. 
Since the Schlegel Village protocol requires B12 testing at admission in addition to every year 
thereafter, for the first time in LTC, incidence of B12 deficiency can be reported. Incidence one year 
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post-admission was estimated at 4% in a subsample of the prevalence study and worsening of status 
in 15 %, providing further support for the need for monitoring. The environmental scan indicated that 
in LTC more broadly, there was no consistency around monitoring of B12 status in Ontario homes; 
follow-up was reported primarily in those who were deficient and even then, only in 85% (34/40) of 
LTC homes. Based on null findings between B12 status at one year and assessed resident 
characteristics, at this point, monitoring must be completed for everyone as no specific subgroup was 
found to be associated with B12 status at one year post admission. That said, incidence, was reported 
on a biased subsample due to the low proportion of follow-up measurements (142/412). This greatly 
impacts the power of the study to detect characteristics that may be associated with a poorer B12 
status. However, based on the evidence at this point in time, a protocol is needed not only for the 
assessment of B12 status but also for monitoring. 
The addition of monitoring B12 status does increase cost. Using the estimate of 71,000 older 
adults 65 years or older living in Ontario LTC homes [91], now assuming a 30% attrition rate due to 
death per year, and an average cost of $12.50 per serum B12 test [42], the cost for B12 monitoring 
using serum B12 for older adults in Ontario is approximately $620,000 Canadian dollars annually. 
There is a need for a formal cost-benefit analysis for monitoring and subsequent treatment and 
prevention of B12-health-related consequences. 
6.4 Methodological lessons learned  
The environmental scan was conducted via phone interviews, which were cumbersome, requiring 
multiple follow-up attempts to collect complete data. If a replication of this study were conducted, 
based on this experience, an online survey would be recommended. Such a survey may result in wider 
reach and response in that responders would complete the questionnaire based on their availability. 
Anonymity would also be assured, which could also have influenced the response in the 
environmental scan conducted. To promote completion, a meaningful incentive would be suggested. 
Provided another opportunity, a question specifically designed to distinguish between characteristics 
of those receiving follow-up testing would be beneficial. This distinction was made for the majority, 
but not all interviews. In addition, to get a sense for the average B12 status at each of the LTC homes, 
a mean and standard deviation of serum B12 levels would have been helpful, however this calculation 
may be infeasible to ask of the staff given time constraints and access to these data within a home. 
While interviewees were asked this question broadly, at best, a guestimate was provided.  
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Due to the Schlegel Village protocol for B12 screening, treatment and monitoring, it was believed 
that a retrospective chart review would be feasible with good internal validity. However, the high 
degree of missing data within the prevalence study potentially influenced the validity. Exclusion 
criteria were based on age at admission (at least 65 years) and admission bloodwork including a 
serum B12 level. Regarding admission bloodwork, 59% of charts reviewed were either missing 
admission bloodwork or this could not be located; 412 resident charts were eligible of 1005 charts 
screened for admission bloodwork. This was exacerbated at one year post admission, where 66% of 
first annual bloodwork was missing; of the initial 412 residents, only 142 first-annual bloodwork 
values were easily located. This suggests that despite implementing clear protocols for resident data 
(i.e., keep admission bloodwork and annual bloodwork in the chart) with best efforts to ensure 
implementation of these protocols, that practice may not always be congruent. For example, residents 
who have lived in LTC for a longer period of time, or have had more health-related incidents tended 
to have thicker charts. These charts are pruned regularly and through discussion with neighbourhood 
coordinators and nurses, it was clear that depending on the neighbourhood, pruning procedures 
varied. At each pruning of the charts, there was an opportunity for admission medications, diagnoses 
and bloodwork to be misfiled. Within a given chart, there were multiple sources of information that 
needed to be accessed from residents’ physical charts (e.g., admission paperwork, CCAC paperwork, 
medications lists, lab results) and each section of residents’ charts were seemingly treated differently 
with respect to chart pruning even within across different neighbourhoods at the same Village. For 
example, if admission bloodwork was included with resident background forms, it tended to be 
present more frequently than if it were filed under lab-work. Frequently review of archived data was 
required to find this admission bloodwork which provided additional challenges; systems for archival 
varied from site to site with some keeping all archives, others moved archived data offsite while a few 
had no filing system for archived data.While admission bloodwork tended to be fairly well 
maintained, annual bloodwork tended to be pruned and excluded from residents’ primary charts. 
Based on exclusion criteria requiring only admission B12 bloodwork, time constraints and the 
primary objective of reporting prevalence, it was infeasible to review all archived data for first annual 
bloodwork.  
An additional challenge for establishing B12 status was the inconsistency of cut-points used by 
labs. Even within the same village a given lab on a different date used different reference ranges. In at 
least one Village, the lab used for blood testing was recently switched and with this change, came a 
different cut-point. In addition to residents’ physical charts, other sources of information needed to be 
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accessed (e.g., MDS) which presented additional opportunities for inconsistencies between sources 
and potential for missing data. Thus, due to the high degree of missing data, it was inappropriate to 
conduct thorough analyses around covariates associated with B12 status at one year post admission. 
Due to these challenges, retrospective chart audits across LTC homes, should be based on readily 
available data, preferably located in an electronic system that has greater likelihood of continual 
updating and completion. 
6.5 Next Steps 
In addition to providing some insight into B12 status, this thesis work also generated further research 
questions. For example, were the null findings of association between B12 status and key medications 
spurious? What is the incidence of B12 deficiency in a larger, non-biased sample and how does this 
compare to this work? What is the efficacy of treatment and are there differences based on treatment 
modality? What is the fidelity to treatment protocols and how might this differ across organizations? 
Does treatment of B12 improve or maintain health-related outcomes? Are there subgroups of older 
adults living in LTC that may be more likely to respond to treatment? Future work would benefit 
from a prospective longitudinal study to minimize missing data and designed to investigate change in 
B12 status over time and with respect to covariates of interest. Future work in this field will provide 
additional evidence and context which will translate into improved recommendations. 
6.6 Concluding Remarks 
This thesis work provided evidence that vitamin B12 deficiency is an issue within LTC as indicated 
through prevalence of 14% at admission, 8% one year post admission and the high proportion (25%) 
of residents in Ontario LTC receiving B12. This work also provides evidence that screening is 
required and that targeted screening would be inappropriate as no resident characteristics excepting 
supplementation status were associated with admission B12 status. While B12 status was generally 
improved, there was sufficient incidence of B12 deficiency and worsening of status that monitoring of 
B12 status is also needed. Prospective studies specifically designed to investigate the association 
between B12 status and risk factors (medications, conditions) are needed to confirm null findings or 
provide counter evidence. In addition, due to a lack of consistency for testing for B12 and monitoring 
B12 status as indicated through the environmental scan, guidelines specific to LTC outlining 
protocols for screening and treatment and monitoring may be warranted. 
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6.7 Recommendations 
Based on the evidence provided by this thesis work, the following preliminary recommendations are 
proposed: 
1. Admission screening is required for all LTC residents. 
2. OHTAC guidelines need further critique and should consider exclusion of LTC residents in 
these recommendations. 
3. Recommendations including a protocol for B12 assessment as well as monitoring is needed. 
4. Physician training may be warranted for appropriate dosing and treatment effectiveness. 
5. Blanket treatment with oral B12 for all LTC residents may be a suitable alternative to 
screening. 
A formal cost-benefit analysis is needed for screening, subsequent treatment, monitoring and 
potential blanket treatment. This analysis should consider increased costs due to increased screening, 
monitoring and associated clinician visits, and addition of oral B12 to the ODBP as well as cost 
reductions due to fewer clinician visits with blanket treatment.
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Appendix A 
Flow diagram of included charts 
 
Village 
Code 
Total 
# 
Resi-
dents 
# Resi-
dents 
Eligible 
Proportion 
Eligible 
Planned 
# to 
Sample 
Actual # 
Sampled 
# Alternates 
required to 
get sample 
Proportion 
planned to 
sample 
Proportion 
Actually 
Sampled 
Pooled 
Sample 
Proportion 
SE Test 
Statistic 
(z) 
P 
1 93 81 0.871 24.35 31 4 0.076 0.075 0.076 0.020 0.065 p >0.4 
2 190 173 0.911 52.01 74 57 0.163 0.179 0.172 0.028 -0.573 p >0.2 
3 187 160 0.856 48.11 62 99 0.151 0.150 0.150 0.027 0.026 p >0.4 
4 119 105 0.882 31.57 41 66 0.099 0.099 0.099 0.022 -0.014 p >0.4 
5 140 125 0.893 37.58 48 78 0.118 0.116 0.117 0.024 0.066 p >0.4 
6 191 166 0.869 49.91 68 80 0.156 0.165 0.161 0.027 -0.299 p >0.3 
7 155 148 0.955 44.50 57 87 0.139 0.138 0.139 0.026 0.057 p >0.4 
8 119 103 0.866 30.97 32 64 0.097 0.077 0.086 0.021 0.938 p >0.1 
  1061  319 413 535       
Total # residents at 9 sites 
(n=1355) 
Exclusion <65 years of age at admission (n=172) 
9 sites preliminarily eligible 
(n=1183) 
Removal of one site due to different practices (n=110) 
8 sites preliminarily eligible 
(n=1073) 
Exclusion of selected residents from one neighbourhood (outbreak) (n=12) 
8 sites – 1 neighbourhood preliminarily eligible (n=1061) 
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Appendix B 
Sources for data collection for the prevalence study 
Resident Assessment Instrument-Minimum Data Set 2.0 for LTC homes (RAI-
MDS or MDS) 
The RAI-MDS 2.0 is a standardized assessment tool used by all LTC homes across Ontario at regular 
intervals (admission, quarterly, after significant change in health status). LTC homes are required to 
conduct a full admission assessment within 14 days of a resident’s admission to LTC. The MDS is 
used to assess a residents care and service needs [146]. For this study, the following subsections were 
of interest since information pertained to factors that may influence B12 status in LTC: weight at 
admission (kgs), height at admission (m), nutritional problem, and weight change. Where: nutritional 
problems is defined as within the past 7 days, the presence of “complaints about the taste of many 
foods”, “regular or repetitive complaints about hunger”, “leaves 25% or more of food uneaten at most 
meals”, none of the above; and weight change is defined as a weight loss or weight gain of 5% or 
more in the last 30 days or 10% or more in the last 180 days. 
Resident Assessment Protocols (RAPs) for cognitive performance and 
activities of daily living 
Based on how questions are answered on the RAI-MDS 2.0, RAPs are used by clinicians in the 
development of a resident’s comprehensive plan of care. For this study, the following RAPs were of 
interest since information pertained to factors that may influence B12 status in LTC: Cognitive 
Performance Scale (CPS) and Activities of Daily Living (ADL-s, ADL-l*).  
A resident’s CPS score is determined using five MDS items. Score values may take on values 
from 0 (intact) to 6 (very severe impairment) where a higher score indicates more cognitive 
impairment. CPS scores were used because this data was easily accessible and has been shown to 
correspond closely with the Mini-Mental State Examination [137]. 
*Activities of daily living are assessed on the MDS across 10 domains: bed mobility, transfer, 
walking in room, walking in corridor, locomotion on unit, locomotion off unit, dressing, eating, toilet 
use, and personal hygiene. From this overall assessment, an ADL short form scale (ADL-s) is 
calculated based on four ADL items: personal hygiene, toilet use, mobility and eating. ADL-s values 
range from 0-16 where a higher score indicates greater difficulty in performing daily activities. 
Similarly, an ADL long form scale (ADL-l) is calculated based on 7 ADL items including the same 
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four as ADL-s with the addition of bed mobility, transfers, and dressing. ADL-l values range from 0-
28 where a higher score again indicates greater difficulty in performing tasks. The ADL-l has been 
shown to be more sensitive to clinical change than the ADL-s and has very good internal consistency. 
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